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Abstract 
Bacterial pathogens are constantly regulating the expression of their genes in 
response to changing environmental conditions and signals from the host. Timely and 
adequate levels of gene expression are essential for obtaining nutrients and evading 
the host immune system. The aim of this thesis was to study regulatory mechanisms 
of virulence-related genes in the bacterial pathogens Francicella novicida and 
Streptococcus pyogenes.  
The focus of chapter one is on the regulation of the important virulence factor 
streptolysin S (SLS), which is responsible for the hemolytic phenotype of the human 
pathogen S. pyogenes. First, we investigated the role of the ribonuclease (RNase) Y 
in the transcriptional and post-transcriptional regulation of sagA, which codes for the 
precursor of SLS. We found that RNase Y promotes the production of a small RNA 
(sRNA) from the sagA transcript. However, no role of RNase Y in the regulation of the 
sagA transcript at the post-transcriptional level was observed. Yet, RNase Y promotes 
sagA transcription indirectly, affecting the hemolytic activity in a growth phase-
dependent manner. Next, we studied the function of sagA 5′ untranslated region (UTR) 
as a putative cis-acting regulatory RNA. We show that the sagA 5′ UTR contains a 
secondary structure that may affect the accessibility to the ribosomal binding site 
(RBS) and that this structure is possibly modulated by direct binding to a ligand. 
Moreover, our results indicate that removing fragments of the 5′ UTR has a negative 
effect on sagA expression, possibly by stabilizing the RBS-blocking structure. While 
investigating the identity of the putative ligand that affects the sagA 5′ UTR structure, 
we developed a method for testing the activity of riboswitches. Using this method, we 
validated three predicted riboswitches in S. pyogenes.  
In chapter two, we characterized the mechanism by which F. novicida CRISPR-
Cas9 (FnoCas9) represses the expression of bacterial lipoproteins (BLPs), allowing 
evasion of the host immune system. We show that FnoCas9 is a dual-function protein 
that, in addition to its canonical DNA nuclease activity, evolved the ability to regulate 
transcription. In this newly-described mechanism, the non-canonical RNA duplex 
tracrRNA:scaRNA guides FnoCas9 to the DNA target located downstream of the 
promoter of the BLP-coding genes (FTN_1103 and FTN_1101), causing transcriptional 
interference. The endogenous targets contain a protospacer-adjacent motif (PAM) and 
a sequence that is complementary to scaRNA, promoting FnoCas9 binding. While the 
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mechanism is reminiscent of DNA targeting in the canonical immunity function of 
CRISPR-Cas9, with scaRNA fulfilling a similar function than crRNA, reduced 
complementarity between scaRNA and the DNA promotes binding but does not allow 
cleavage. This system can also be engineered to repress other genes, expanding the 
toolbox of CRISPR applications.  
 
Zusammenfassung 
Pathogene Bakterien passen ihre Genexpression konstant an sich verändernde 
Umweltbedingungen und Einflüsse des Wirtes an. Zeitlich abgestimmte und adäquate 
Genexpressionslevel sind essentiell für die Nährstoffaufnahme und um einer 
Immunantwort des Wirtes zu entgehen. Ziel dieser Arbeit war es, die regulatorischen 
Mechanismen von Virulenz-assoziierten Genen in den Pathogenen Francisella 
novicida und Streptococcus pyogenes zu untersuchen. 
 Kapitel eins befasst sich mit der Regulation des wichtigen Virulenzfaktors 
Streptolysin S (SLS), welcher für den hämolytischen Phänotyp des humanpathogenen 
Bakteriums S. pyogenes verantwortlich ist. Zunächst untersuchten wir die Funktion der 
Ribonuklease (RNase) Y während der transkriptionellen und posttranstrikptionellen 
Regulation des Gens sagA, welches für die Vorstufe von SLS kodiert. RNase Y 
begünstigte die Produktion einer kleinen RNA (small RNA – sRNA) vom sagA 
Transkript. Jedoch konnten wir keine Beteiligung der RNase an der 
posttranskriptionellen Regulierung des sagA Transkripts beobachten. Dennoch 
förderte RNase Y die Transkription von sagA indirekt, und damit, abhängig von der 
Wachstumsphase, die hämolytische Aktivität. Weiterhin untersuchten wir die Funktion 
der 5′-untranslatierten Region (UTR) des sagA Transkripts als ein putatives cis-
wirkendes Element. Wir konnten zeigen, dass diese 5′ UTR eine Sekundärstruktur 
besitzt, die die Zugänglichkeit der ribosomalen Bindungsstelle (RBS) beeinflussen 
könnte, wobei die Struktur wahrscheinlich durch die Bindung eines Liganden moduliert 
wird. Außerdem deuten unsere Experimente darauf hin, dass die Deletion einzelner 
Abschnitte der 5′ UTR einen negativen Effekt auf die Expression von sagA hat, 
möglicherweise durch die Stabilisierung der RBS-blockierenden Struktur. Um den 
putativen Liganden zu identifizieren, der die Struktur der 5′ UTR von sagA beeinflusst, 
haben wir eine Methode entwickelt um die Aktivität von Riboswitches zu analysieren. 
Mit dieser Methode konnten wir drei putative Riboswitches in S. pyogenes validieren. 
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 In Kapitel zwei charakterisierten wir den Mechanismus mit dem CRISPR-Cas9 
aus F. novicida (FnoCas9) die Expression bakterieller Lipoproteine (BLPs) unterdrückt 
und damit dem Immunsystem des Wirtes entgeht. Wir konnten zeigen, dass FnoCas9 
eine duale Funktion besitzt, die es dem Protein ermöglicht nicht nur DNA zu schneiden 
(kanonische Funktion), sondern auch Transkriptionsprozesse zu regulieren. Diese 
erstmals beschriebene Aktivität umfasst die Bindung von FnoCas9 an den nicht-
kanonischen RNA-Duplex bestehend aus tracrRNA und scaRNA, wodurch der Protein-
RNA Komplex an einen DNA Abschnitt stromabwärts des Promoters zweier BLP-
kodierender Gene (FTN_1103 und FTN_1101) bindet und somit eine transkriptionelle 
Interferenz hervorruft. Diese endogene Bindungsstelle besitzt ein benachbartes Motiv 
(protospacer-adjacent motif – PAM) und eine scaRNA-komplementäre Sequenz, 
durch die der FnoCas9-RNA Komplex binden kann. Dieser Mechanismus erinnert an 
die kanonische DNA-bindende Immunfunktion von CRISPR-Cas9, wobei die scaRNA 
eine ähnliche Rolle wie die crRNA einnimmt. Jedoch begünstigt die verminderte 
Komplementarität zwischen scaRNA und der DNA zwar die Bindung, jedoch nicht die 
Spaltung der DNA. Dieses System kann auch dahingehend verändert werden, um die 
Expression anderer Gene zu reprimieren und erweitert damit das Repertoire an 
CRISPR-basierten Anwendungsmöglichkeiten. 
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Chapter One:  
Regulation of streptolysin S expression by a small 
RNA and RNase Y in Streptococcus pyogenes  
 
Regulatory RNAs in bacteria  
Bacterial non-coding RNAs (ncRNAs) are involved in the regulation of central biological 
functions such as energy metabolism, quorum sensing, biofilm formation, stress 
response, adaptation to growth conditions and pathogenesis (Michaux et al., 2014). 
Traditional regulatory ncRNAs can be divided in four classes according to their 
mechanism of action: a) protein-activity modulation, b) antisense c) 5′-encoded 
regulatory elements (riboswitches and thermosensors) and, d) trans-encoded. Lately, 
CRISPR (clustered, regularly interspaced palindromic repeats) has emerged as an 
important new class of ncRNAs that are involved in defense against bacteriophage and 
plasmid invasion (see chapter two). 
 Trans-encoded ncRNAs base-pair with an mRNA target and activate or repress 
translation by diverse mechanisms. When the ncRNA base-pairs near or on the 
ribosome-binding site (RBS) of the target mRNA, it prevents the ribosome from binding 
to the mRNA and, therefore, inhibits translation. In other cases, the ncRNA base-pairs 
upstream of the RBS and promotes translation by inhibiting formation of secondary 
structures that, in the absence of the ncRNA, block access to the RBS. Additionally, 
trans-encoded ncRNAs can affect mRNA stability by promoting or inhibiting specific 
ribonuclease (RNase) activity. mRNA-ncRNA base-pairing can, for example, generate 
double-stranded (ds)RNA stretches that protect the RNA from single-stranded specific 
RNases. In other cases, ncRNA binding exposes single-stranded regions that, in the 
absence of the ncRNA would be double-stranded, allowing single strand(ss)-specific 
RNases to cleave. Of course, the opposite is also possible, i.e., ssRNA regions of the 
target mRNA that become ds when bound to the ncRNA, promoting ds-specific-
RNases cleavage. Usually these kinds of ncRNAs interact via imperfect 
complementary sequences with their targets, allowing one ncRNA to have multiple 
targets (Storz et al., 2011). 
Antisense RNAs (asRNAs) are cis-encoded ncRNAs transcribed from the 
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opposite strand of their targets and, consequently, fully complementary to them (Georg 
and Hess, 2018). asRNAs regulate gene expression by affecting transcription, mRNA 
stability or translation. mRNA stability and translation by cis-encoded sRNAs are 
regulated by similar mechanisms as those observed for trans-encoded ncRNAs. For 
asRNA-mediated transcriptional regulation two distinct mechanisms have been 
proposed: interference and attenuation. Interference means that simultaneous 
transcription from the sense and antisense strands cause the RNA polymerases to 
collide, interrupting the process. On the other hand, attenuation occurs when the 
asRNA causes the formation of a transcriptional terminator in the target mRNA (Sesto 
et al., 2013). In addition, ncRNAs can regulate protein activity either by acting as co-
factors essential for protein activity or by antagonizing or sequestering proteins 
(Waters and Storz, 2009).  
Finally, thermosensors and riboswitches regulate transcription or translation by 
changing the target RNA structure in response to changes in temperature or presence 
of a specific molecule, respectively (Ignatov and Johansson, 2017). Riboswitches will 
be described in more detail in the following section.  
 
Riboswitches  
Riboswitches are RNA structures that specifically bind small molecules and modify 
gene expression. Typically, riboswitches are found in the 5′ UTR of mRNAs but can 
also be present in ncRNAs such as as and protein-sequestering RNAs (DebRoy et al., 
2014; Mellin et al., 2013, 2014). Furthermore, some riboswitch-containing transcripts 
also act as trans-encoded ncRNAs (Loh et al., 2009). Known riboswitch ligands include 
ions, cofactors (e.g. vitamins) and modified nucleotides (nt) (such as second 
messengers). Riboswitches are widely distributed in bacteria and can also be found in 
some fungi, algae and plants (Barrick and Breaker, 2007; Breaker, 2012). To date, 
approximately 40 structurally distinct riboswitch classes have been discovered (Lotz 
and Suess, 2018). Even though each riboswitch class senses a specific ligand, some 
ligands can be sensed by more than one riboswitch class (Lotz and Suess, 2018).  
Riboswitches consist of two elements: a ligand-sensing domain, known as an aptamer, 
and a regulatory domain, called expression platform. In response to changes in ligand 
concentration the expression platform undergoes a conformational change that 
regulates expression of the downstream transcript. Regulatory mechanisms of 
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riboswitches include modulation of transcription, translation, transcript stability and 
processing (Barrick and Breaker, 2007). The expression platform of transcriptional 
riboswitches can adopt two mutually exclusive conformations: an intrinsic 
transcriptional terminator that prevents transcription elongation, or an anti-terminator 
that allows transcription to continue. Similarly, translational riboswitches take two 
alternative structures that permit or block access to the RBS. Other, less-studied 
riboswitch mechanisms involve Rho-dependent transcriptional termination and 
modulation of ribonucleolytic processes, either by self-cleaving ribozymes or 
ribonucleases (Hollands et al., 2012; Lee et al., 2010; Winkler et al., 2004).  
 In some cases, multiple regulatory mechanisms can be integrated in one 
expression platform to give rise to more complex systems, for example by 
simultaneously regulating translation initiation and cleavage by an RNase (Caron et 
al., 2012). Ligand binding usually inhibits expression of the adjacent gene although 
upregulation has also been reported (Mandal and Breaker, 2004; Sudarsan et al., 
2008). 
 
Discovery of riboswitches and ligand identification  
In order to fulfil their function, aptamers need to specifically recognize their ligand at 
physiological concentrations (in the pM to mM range, depending on the riboswitch) and 
discriminate between very similar molecules. This imposes constraints at the level of 
structure and sequence, which makes the aptamer the most conserved part of 
riboswitches (Breaker, 2011). This aptamer conservation has been successfully 
exploited to predict riboswitches (Ames and Breaker, 2010). However, bioinformatics 
approaches have thus far focused on structures that are widely distributed across 
species (Barrick et al., 2004; Weinberg et al., 2007). It is therefore likely that 
riboswitches with narrower distributions have been overlooked. In many cases, the 
identity of the ligand has been inferred based on the genetic context (Barrick et al., 
2004). Yet, finding the ligand in cases where the function of the adjacent gene is 
unknown can be challenging (Meyer et al., 2011). Moreover, small sequence variations 
of even a single substitution can alter the specificity of the riboswitch, making it difficult 
to predict the identity of the ligand even for closely related riboswitches (Weinberg et 
al., 2017). Therefore, individual riboswitch variants still need to be experimentally 
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validated.  
Traditionally, a technique called in-line probing has been used to evaluate the 
binding of ligands to their corresponding riboswitch (Regulski and Breaker, 2008). In-
line probing takes advantage of the property of RNA to spontaneously self-cleave in a 
structure-dependent manner, with single-stranded regions being more prone to 
degradation (Regulski and Breaker, 2008). Therefore, denaturing-gel electrophoresis 
analysis of 5′-end labelled RNA after incubation with putative ligands results in a band 
pattern that provides structural information. Further analysis can even help estimating 
differences in affinity between closely related molecules (Regulski and Breaker, 2008). 
In-line probing has also been used to identify the ligand of a predicted riboswitch from 
a complex mix of metabolites (Nelson et al., 2013). However, this approach is laborious 
and, since it renders no functional information, can lead to false positive hits.  
Currently, no high-throughput method for identifying ligands of predicted 
riboswitches exists. In addition to aiding the discovery of endogenous ligands of 
riboswitches, such a method could be used to identify non-natural ligands of known 
riboswitches. This knowledge could be harnessed for the development of new 
antibiotics (Aghdam et al., 2016). 
Streptococcus pyogenes 
Streptococcus pyogenes is a Gram-positive bacterium that is only known to infect 
humans. It forms chains of cocci and causes the complete lysis of red-blood cells (beta-
hemolysis). Colonization by S. pyogenes can have a wide variety of outcomes, from 
asymptomatic carriage and mild local colonization in the skin or throat, to deep-tissue 
and systemic invasions (bacteremia). Pharyngitis (sore throat) is the most frequent 
disease caused by S. pyogenes. In addition, S. pyogenes is the predominant non-viral 
cause of pharyngitis (Wessels, 2016). Throat infection, and other streptococcal 
diseases, can be accompanied by scarlet fever, a skin rash that is likely caused by 
exposure to streptococcal toxins (Wessels, 2016). 
  S. pyogenes can also infect different skin layers, causing impetigo or erysipelas 
when the infection is at the superficial keratin layer and epidermis, respectively 
(Stevens and Bryant, 2016). Infection of the deeper tissue can lead to more severe 
diseases such as necrotizing fasciitis, which can have a mortality rate of up to 80 % 
(Stevens and Bryant, 2016). Superantigens and other virulence factors produced by 
S. pyogenes may cause an excessive immune response resulting in streptococcal 
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toxic shock syndrome and organ failure (Stevens and Bryant, 2016).  
Finally, cross-reactivity with the antigens that are present on the surface of 
S. pyogenes can also lead to post-streptococcal autoimmune sequelae such as acute 
rheumatic fever leading to rheumatic heart disease or post-streptococcal 
glomerulonephritis (Cunningham, 2016).  
 
Hemolysins in Streptococcus pyogenes 
S. pyogenes secretes multiple virulence factors that help the bacteria obtaining 
nutrients and in the defense against the immune system of the host (Hynes and Sloan, 
2016). Among the most studied virulence factors are the cytolysins, streptolysin S 
(SLS) and streptolysin O (SLO).  
 
Streptolysin O 
SLO is an oxygen-labile pore-forming cytotoxin that is translated as a 69 kDa protein 
which is activated by a proteolytic cleavage and exported to the extracellular milieu 
(Hynes and Sloan, 2016). The mature SLS is then inserted in the membrane of host 
cells in a cholesterol-dependent manner and oligomerizes forming a pore (Hynes and 
Sloan, 2016). In addition to cholesterol, a galactose-containing receptor is involved in 
SLO-mediated pore formation in some conditions (Mozola and Caparon, 2015; Shewell 
et al., 2014). In macrophages, pore formation leads to caspase-dependent apoptosis 
(Timmer et al., 2009). Consistently, SLO negative mutants are less resistant to killing 
by macrophages when compared to the isogenic SLO positive strains (Bastiat-Sempe 
et al., 2014), and are attenuated in virulence (Fontaine et al., 2003; Limbago et al., 
2000). Following phagocytosis, SLO prevents acidification, allowing the bacteria to 
survive (Bastiat-Sempe et al., 2014). SLO also activates neutrophils (Nilsson et al., 
2006), promotes inflammation and boosts the immune response (Harder et al., 2009). 
SLO is immunogenic and has been proposed as a potential candidate for vaccine 
development (Chiarot et al., 2013). 
 
Streptolysin S  
SLS is an oxygen-stable thiazole/oxazole-modified microcin toxin produced by 
S. pyogenes and other streptococcal species (Molloy et al., 2011). The genes that are 
necessary for the production and secretion of SLS are encoded in the nine-gene 
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operon sag (Nizet et al., 2000). The first gene of the operon, sagA, encodes the SLS 
precursor peptide that is modified and exported by the remaining Sag proteins. The 
genes sagBCD code for a trimeric oxazole/thiazole synthase complex (SagBCD) that 
modifies SagA conferring it cytolytic activity (Lee et al., 2008). The SagE protease 
removes the leader of the modified SagA, giving rise to the active SLS toxin (Maxson 
et al., 2015). Once modified, the active SLS is exported via an ABC transporter formed 
by the SagGHI proteins (Datta et al., 2005). The remaining Sag protein (SagF) has an 
unknown function but it is also essential for hemolytic activity (Nizet et al., 2000). 
 
Role in Virulence 
The sag operon is conserved across almost all studied strains (Nizet et al., 2000; 
Yoshino et al., 2010) suggesting it is important for the survival of S. pyogenes. Indeed, 
mutant strains that are unable to produce SLS are attenuated in virulence and cause 
less tissue damage in most murine models of infection, compared to their 
corresponding isogenic wild type (WT) strain (Betschel et al., 1998; Datta et al., 2005; 
Engleberg et al., 2004). The contribution of SLS to virulence varies depending on the 
model and the studied strain, with some models showing little contribution to survival 
or pathogenicity (Fontaine et al., 2003; Kinkel and McIver, 2008). In some strains, the 
relative contribution of SLS to pathogenesis varies in different strains depending on 
the expression of other factors such as the capsule (Sierig et al., 2003). It was shown 
that sagA deletion mutant is attenuated in a murine invasive model only when the strain 
is also unable to produce capsule (Sierig et al., 2003).  
Despite the limitations of current infection models for S. pyogenes (Watson et 
al., 2016), it is now widely accepted that SLS is an important virulence factor for S. 
pyogenes (Hynes and Sloan, 2016). However, the specific functions of SLS during 
infection are less clear. The proposed roles of SLS include defense against the immune 
systems of the host, dissemination across tissues, and ensuring nutrient availability 
(Molloy et al., 2011). 
  The implication of SLS in defense against the immune system of the host is 
supported by evidence showing that SLS mediates neutrophil and macrophage killing. 
Indeed, it was shown that S. pyogenes cytotoxicity on macrophages is mostly mediated 
by SLS and SLO (Goldmann et al., 2009). It has also been observed that S. pyogenes 
kills neutrophils in an SLS-dependent manner (Miyoshi-Akiyama et al., 2005). In 
addition to its observed cytotoxicity, SLS is able to inhibit neutrophil recruitment to the 
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site of infection (Feng et al., 2017; Lin et al., 2009). Consequently, an SLS-deficient 
mutant was attenuated in virulence and was associated with an increased 
accumulation of neutrophils compared to the isogenic WT strain (Feng et al., 2017; Lin 
et al., 2009). In agreement with these results, a recent study has found that SLS 
activates pain-sensing neurons, which in turn block neutrophils recruitment (Pinho-
Ribeiro et al., 2018). 
Apart from its role in defense, SLS has been suggested to facilitate the 
dissemination of S. pyogenes across different tissues. Accordingly, the ability of S. 
pyogenes to translocate across epithelial cells in vitro was reduced in a SLS negative 
mutant compared to the WT (Sumitomo et al., 2011). Interestingly, SLS acts indirectly 
via the host protease calpain to mediate proteolytic cleavage of intercellular junctions 
(Sumitomo et al., 2011). A recent study has also linked SLS and SLO with biofilm 
production in cell cultures and microcolony formation in a mouse model of necrotising 
fasciitis (Vajjala et al., 2018). This study shows that this is dependent on the ability of 
the streptolysins to cause endoplasmic reticulum stress and proposes that this 
promotes biofilm formation, dissemination and proliferation indirectly through the 
release of unknown signals (Vajjala et al., 2018). 
 
Mode of action 
Despite the fact that SLS has been known to lyse cells since 1938 (Molloy et al., 2011), 
the precise mechanism remains largely unknown. The most detailed biochemical study 
so far shows that the interaction between SLS and the ion transporter Band 3 mediates 
lysis of red blood cells by facilitating influx of Cl− (Higashi et al., 2016). Furthermore, 
inhibition of Band 3 activity reduces skin lesion size to similar levels than deleting sagA 
in a murine model of skin infection (Higashi et al., 2016). However, since the 
expression of the Band 3 protein is restricted to erythrocyte, the mechanism that 
mediates SLS-dependent lysis in other cell types is currently unknown. 
  
Regulation  
As mentioned above, SLS is an important virulence factor in S. pyogenes. As such, 
the conditions in which this toxin is produced have been broadly studied. It is important 
to note that due to inter-strain variability it is impossible to make general conclusions 
about the role some of these factors have on SLS regulation. Furthermore, even if the 
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regulators themselves are conserved, their regulon might vary in different strains 
and/or conditions. However, because the cues and pathways that affect SLS 
production are likely related to its function, some general conclusion can be drawn out 
of this information. 
The complete signal transduction pathway linking the input signal to changes in 
SLS production has not been traced in most cases. Yet, various conditions and cues 
that affect sagA expression (and some of its regulators) have been discovered. These 
include nutrient availability (e.g. glucose and nitrogen), growth in blood, saliva or 
conditioned media and presence of small molecules (such as homoserine lactones, 
asparagine and SLS autoregulation) (Baruch et al., 2014; Graham et al., 2005; Salim 
et al., 2007; Saroj et al., 2016, 2017; Shelburne et al., 2010; Steiner and Malke, 2001; 
Sundar et al., 2018; Valdes et al., 2018). Some of the factors that modulate SLS 
production include stand-alone regulators (e.g. Mga, CcpA), two-component systems 
(e.g CovR/S, Ihk/irr, SptR/S), RNases (i.e. RNases Y, J1, J2, PNPase) and a sRNA 
(fasX) (Vega et al., 2016).  
In spite of the body of knowledge that has accumulated regarding conditions 
that affect SLS production, there is little information about the mechanisms governing 
the transcriptional regulation of sagA and even less about the factors affecting SLS 
production at the post-transcriptional level. The cases where the specific signal that is 
sensed is known or the regulatory mechanism has been elucidated, are explained in 
more detail below. 
 
Regulation by small molecules and quorum sensing 
Bacteria rely on the production and detection of small molecules in order to sense the 
presence and abundance of other bacteria in the surrounding environment, a system 
called quorum sensing (QS).  
 Sil is a QS system composed of the SilAB two-component system (TCS), the 
SilDE ABC transporter and the SilCR signalling peptide (Hidalgo-Grass et al., 2002). 
Between 12% and 25% of S. pyogenes isolates encode Sil, with some bacteria having 
incomplete or non-functional systems (Jimenez and Federle, 2014). It has been shown 
that the pheromone SilCR upregulates sagA expression (Salim et al., 2008). 
Interestingly, this effect was observed even in absence of SilAB suggesting the 
presence of other mechanisms to sense SilCR from other strains or species, even in 
the absence of the complete Sil QS system (Salim et al., 2008). 
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 Other QS signaling molecules have been recently implicated in sagA regulation. 
Acyl homoserine lactones (AHLs), typically involved in bacterial QS systems, were 
shown to enter S. pyogenes cells through the ferrichrome transporter FtsABCD and 
repress sagA expression (Saroj et al., 2017). Regulation of sagA by AHLs is dependent 
on the QS transcriptional regulator LuxR that was shown to bind sagA promoter (Saroj 
et al., 2017). However, the exact mechanism mediating this regulation is unclear, as 
LuxR also seems to bind sagA promoter in the absence of AHLs, at least in vitro. In 
addition, the inhibitory effect of AHLs was not observed in all the strains studied, 
suggesting that it might be strain-specific (Saroj et al., 2017). Interestingly, the same 
study detected an increase in the intracellular iron concentration after addition of AHLs 
and proposed that inhibition of sagA expression is mediated by iron (Saroj et al., 2017). 
Though these hypotheses need further investigation, they are in line with the proposed 
role of SLS in iron acquisition (Molloy et al., 2011). 
In contrast, a previous study found that sagA expression was upregulated in 
high (1000 µM) compared to low (1 µM) iron concentrations (Salim et al., 2007), which 
is in agreement with the upregulation of sagA in blood (Graham et al., 2005). The 
authors proposed that high iron concentrations mimic the environment inside the host 
phagosome and SLS production allows S. pyogenes to escape (Salim et al., 2007). It 
is therefore possible that different iron concentrations, or iron signalling under different 
conditions, have opposing effect. 
In addition to AHL, SLS itself has been shown to act as a QS signal via an 
unknown mechanism (Salim et al., 2007). Conditioned media from WT S. pyogenes 
but not from a sagA deletion mutant induced sagA expression (Salim et al., 2007). The 
same effect was observed upon addition of purified SLS to the medium (Salim et al., 
2007). This is in contrast to a previous study showing that addition of conditioned media 
had no effect on sagA expression (Mangold et al., 2004). Therefore, whether SLS acts 
as a QS molecule or whether it is strain specific remains unclear. 
The amino acid asparagine is the only other example where the concentration 
of a specific molecule is linked to sagA regulation. A study by Baruch and colleagues 
has found that depletion of asparagine induces expression of the sag operon partly 
through the TrxRS TCS (Baruch et al., 2014). In addition, SLS and SLO cause 
endoplasmic reticulum stress, leading to the production of asparagine. Since 
asparagine promotes S. pyogenes growth in vitro, the authors proposed that one of 
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the functions of SLS and SLO is to induce the release of asparagine in order to favour 
growth (Baruch et al., 2014). 
 
Direct transcriptional regulation 
Of all the known transcriptional regulators that affect sagA expression, only two in 
addition to LuxR (which seems to act in strain-specific manner) have been shown to 
bind the sagA promoter region: CcpA and CovR. 
CcpA is the catabolite control protein that regulates carbohydrate utilization via 
the phosphoenolpyruvate phosphotransferase system (PTS), which monitors 
availability of different carbon sources (Deutscher et al., 2006). It was shown that CcpA 
represses sagA in response to carbon catabolite repression (DebRoy et al., 2016; 
Kietzman and Caparon, 2010; Kinkel and McIver, 2008; Shelburne et al., 2008). 
However, there is contradictory evidence as to whether this regulation is direct or 
indirect. While Kietzman and Caparon, 2010 saw no interaction between CcpA and a 
putative CcpA-binding site upstream of the sagA promoter, others have observed a 
direct interaction (Kinkel and McIver, 2008; Shelburne et al., 2008). Nonetheless, the 
regulation of sagA by CcpA is conserved across multiple serotypes (DebRoy et al., 
2016) and might explain, at least in part, the repression of sagA expression in the 
presence of glucose (Sundar et al., 2018; Valdes et al., 2018). 
CovR/S is the TCS that controls the expression of several virulence factors. 
CovS responds to Mg2+ and host antimicrobial peptides (Gordon, 2007; Gryllos et al., 
2003, 2008) and phosphorylates the response regulator CovR. Phosphorylated CovR 
represses sagA expression by binding two sites located in the vicinity of the sagA 
promoter (Gao et al., 2005; Horstmann et al., 2014). Interestingly, CovR does not 
require CovS to regulate sagA (Dalton and Scott, 2004; Horstmann et al., 2014), 
suggesting there are other mechanisms for CovR phosphorylation. Indeed, CovR 
reversible phosphorylation by the Ser/Thr kinase (SP-STK) and phosphatase (SP-
STP) has been shown to affect sagA expression (Agarwal et al., 2011). 
 
Post-transcriptional regulation 
In addition to the effect that transcriptional regulators have on sagA expression, there 
is some evidence, albeit scarcer, indicating that production of SLS might also be 
regulated at the post-transcriptional level. Four RNases have been shown to affect 
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sagA transcript abundance and/or stability (PNPase, RNase Y and RNases J1/J2) 
(Barnett et al., 2007; Bugrysheva and Scott, 2010; Kang et al., 2010). 
In 2007, Barnett and colleagues proposed that two factors are responsible for 
the increase in sagA transcript abundance at early stationary (ES) growth phase as 
compared to mid-logarithmic (ML) (Barnett et al., 2007). The first is an increment in 
promoter activity and the second a stabilization of the sagA transcript (Barnett et al., 
2007). They further discovered that the 3′ to 5′ exoribonuclease polynucleotide 
phosphorylase (PNPase) is involved in decay of the sagA transcript (Barnett et al., 
2007). Indeed, while deletion of two other 3′ to 5′ exoRNases (RNase R and YhaM) 
had no effect in transcript stability, sagA mRNA was 8-fold more stable in a mutant 
lacking PNPase (Barnett et al., 2007). Though these results do not necessarily mean 
that PNPase is involved in regulating hemolysis, the difference in sagA stability 
between the two growth phases suggest that SLS production might be regulated at the 
transcriptional and post-transcriptional levels. 
Other RNases involved in the sagA mRNA degradation are RNases J1 and J2, 
which are essential in S. pyogenes (Bugrysheva and Scott, 2010). RNase J1 is the 
only described 5′-to-3′ exoRNase in bacteria and might act as an endoribonuclease in 
some cases, though this latter activity is still under debate (Durand and Condon, 2018). 
RNase J2 is an orthologue of RNase J1 whose activity is less understood but seems 
to form a complex with RNase J1 (Durand and Condon, 2018). Using conditional 
mutants of RNases J1 and J2, Bugrysheva and Scott show that the decay of sagA 
transcript initiates earlier when the expression of the RNases is induced (Bugrysheva 
and Scott, 2010). These results indicate that RNases J1 and J2 might be involved in 
the turnover of sagA transcript (Bugrysheva and Scott, 2010). 
RNase Y is a single-stranded specific endoRNase that is anchored to the inner 
side of the membrane (Durand and Condon, 2018). This enzyme is important for the 
virulence in various Gram-positive bacteria including S. aureus, C. perfringens, and S. 
pyogenes (Chen et al., 2013; Kaito et al., 2005; Kang et al., 2010; Khemici et al., 2015; 
Marincola et al., 2012; Nagata et al., 2008; Obana et al., 2017). In B. subtilis, RNase 
Y has an impact on the transcript abundance of most riboswitches (DeLoughery et al., 
2018) and other cis-acting RNA structures (Laalami et al., 2013). It has been shown 
that RNase Y cleaves the SAM-binding riboswitch, preferably in the presence of the 
ligand (Shahbabian et al., 2009). This suggests that, at least in B. subtilis, RNase Y is 
a key player in riboswitch-mediated regulation.  
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The biochemical constraints that determine the specificity of RNase Y remain 
largely unknown. In S. aureus RNase Y was reported to cleave preferably after G in 
A/U-rich regions (Khemici et al., 2015) and the requirement for a secondary structure 
downstream of the cleavage site was proposed (Marincola and Wolz, 2017). A recent 
study from our laboratory showed that a presence of a G is required for RNase Y 
cleavage but failed to identify any structural requirement (Broglia et al., 2018).  
In S. pyogenes, RNase Y was reported to regulate the expression of 
approximately 29% of the genome, including sagA, which was downregulated in a 
mutant strain unable to produce RNase Y compared to the WT (Kang et al., 2010). 
Although these studies open the possibility that these RNases are involved in the post-
transcriptional regulation of sagA, the mechanism and the extent of these effects 
remain to be investigated. 
 
Results 
 
RNase Y is involved in the processing of sagA transcript  
A previous study from our laboratory that used RNA sequencing (RNAseq) and 
Northern blot analyses to discover novel sRNAs in S. pyogenes showed that sagA 
mRNA contains a 144 nt-long 5′ UTR that gives rise to a sRNA (Rhun et al., 2016).  
 Because RNase Y was reported to regulate sagA expression (Kang et al., 
2010), it is possible that RNase Y cleaves the sagA 5′ UTR thus regulating sagA 
expression. Indeed, a ~120 nt-long sRNA was detected in the WT and the Δrny 
complemented (Δrny::rny) strains but not in the Δrny strain by Northern blot analyses 
(Figure 1. A-B). Interestingly, even though RNase Y is produced at similar levels 
throughout the growth phases (Lécrivain, unpublished), this sRNA was observed in ML 
but not in ES growth phases (Figure 1. B), suggesting that it is produced by a regulated 
process. Therefore, we first investigated the mechanism by which the sagA transcript 
was processed and the exact location of the processing site. 
Several attempts to determine the exact position of the cleavage by primer 
extension were unsuccessful (data not shown). It is possible that the downstream 
fragment produced by RNase Y processing was too unstable to be detected by primer 
extension. Indeed, cleavage products were not detected with a probe that anneals to 
the sagA coding sequence (CDS) (Figure 1. C). To overcome these limitations, we 
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performed RNA circularization followed by reverse transcription-PCR of the sRNA and 
sanger sequencing. Yet, transcript ends corresponding to the end of the sRNA were 
not detected (data not shown). A possible explanation is that the ratio between 
processed and unprocessed transcripts is low, reducing the probability of detecting the 
processing site by this technique. In support of this, RNA stability assays showed that 
the sagA primary transcript was highly stable in the WT and in the Δrny mutant, in both 
growth phases (Figure 1. D). Because processing of the primary transcript would 
appear as a reduction of band intensity, this suggested that the rate at which the 
primary transcript was processed is low.  
As an alternative approach to determine the exact location of RNase Y 
cleavage, we generated deletions and point mutations in the area surrounding the 
RNase Y putative cleavage site. First, we estimated the approximate location of the 3′ 
end using the size of the sRNA in the Northern Blot. Then, we constructed a 
transcriptional reporter fusion to the firefly luciferase gene expressing sagA 5′ UTR 
under the P23 constitutive promoter (P23-5′ UTR) and introduced substitutions in the 
RNase Y putative cleavage site (Figure 1. A). Because it was recently reported that 
RNase Y requires a guanosine (G) adjacent to the cleavage site to be active (Broglia 
et al., 2018), we introduced G-to-A substitutions in all Gs in this area (Figure 1. A). In 
addition, we deleted up to 10 nucleotides surrounding the putative cleavage site 
(Figure 1. A). However, both the substitutions and the deletions failed to inhibit the 
production of the sRNA (Figure 1. E). Preliminary results suggested that the reporter 
fusion that contains the WT sequence gives rise to the sRNA in Δrny as well as in the 
WT (data not shown). Though these results need to be confirmed, this raises the 
possibility that the sRNA is produced by other mechanisms and that RNase Y affects 
its production indirectly.  
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Figure 1. RNase Y affects expression and processing of the sagA transcript. A) Schematic 
representation of the sagA locus (top). Annealing sites of Northern blot probes are indicated with red 
arrows. Undulated lines represent the transcripts detected by Northern Blot, approximate sizes of 
transcripts are indicated. The bottom panel shows a close-up of the region surrounding the RBS 
indicating the sequence and the position of deletions/substitutions introduced in the sagA 5′ UTR. 
Numbers indicate coordinates relative to the sagA start codon. B and C) Northern blot analysis of sagA 
transcript during mid-logarithmic (ML) and early stationary (ES) growth phases in wild-type (WT), RNase 
Y deletion (Δrny), complementation (Δrny::rny) strain and 5′ UTR sagA deletion (Δ5′UTR) strain. sagA 
deletion strain (ΔsagA) was used as a control to confirm probe specificity. D) Stability assay of sagA 
transcript in WT and Δrny grown until ML (left panel) or ES (right panel) growth phases. Transcription 
was stopped using rifampicin and samples were taken as indicated. Numbers indicate time points in 
minutes. Approximately 3-fold more RNA was used for Δrny than for WT to compensate for lower initial 
transcript abundance. E) Northern Blot analysis of ΔsagA transformed with the empty vector (pEC2174), 
the vector containing the WT sagA 5′ UTR or the 5′ UTR with the mutations described in B, the WT strain 
was included as a control. The 5S rRNA was used as a loading control for all Northern blots. In E, the 
size of the 5S RNA band is approximately the same as the band for the sRNA, which interferes with the 
loading control making it impossible to make any conclusion about the abundance of the sRNA. 
However, the presence or absence of the sRNA can be evaluated.  The probes used in each experiment 
is indicated at the bottom. Probe 1 (OLEC3273) anneals at positions −122 to −100 of sagA 5′ UTR (see 
also A). Probe 2 (OLEC7883) is complementary to the last 26 nt of sagA CDS (see A). 
 
RNase Y regulates sagA mRNA expression 
As mentioned above, RNase Y regulates sagA transcript abundance (Kang et al., 
2010). In agreement, sagA transcript levels were 4-fold lower in Δrny compared to WT 
in ML growth phase (Le Rhun, RNAseq differential expression analysis unpublished). 
Furthermore, Northern Blot analyses showed that the abundance of sagA primary 
transcript was lower in Δrny than in the WT or the complemented (Δrny::rny) strain, 
regardless of the growth phase (Figure 1. B-C). Production of the sRNA should result 
in lower primary transcript levels, therefore the RNase Y-dependent upregulation of 
the primary transcript must result from a different process. This indicates that RNase 
Y has two opposing effects on the abundance of primary sagA transcript (one at the 
transcriptional and one at the post-transcriptional levels).  
In order to investigate the contribution of the post-transcriptional effect, we 
analyzed the expression of the constitutive P23-5′UTR fusion in the WT and Δrny 
(Figure 2. A). However, no difference in expression was observed between the two 
strains in either ML and ES growth phases (Figure 2. A). This is in agreement with the 
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fact that the abundance of the processed transcript is low in comparison to the primary 
transcript (Figure 1. B), suggesting that it was produced at a slow rate.  
It is possible that under conditions where the processing rate increases, the 
post-transcriptional effect is stronger. To investigate the effect that removing sagA 5′ 
UTR had on transcript abundance, we used the Δ5′ UTR strain, which contained a 
deletion of the first 122 nt of sagA 5′ UTR in the chromosome of S. pyogenes (leaving 
22 nt upstream of the start codon, Figure 1. A). Northern blot analyses showed a lower 
sagA mRNA abundance in Δ5′ UTR compared to the WT strain, in both growth phases 
(Figure 1. A). This suggested that a processing event that removes the sagA 5′ UTR 
from the transcript would have a negative impact on sagA transcript abundance.  
To investigate the role of RNase Y in the transcriptional regulation of sagA 
independently of any post-transcriptional effect, we constructed a fusion of sagA 5′ 
UTR to the firefly luciferase reporter gene containing the PsagA promoter without the 
sagA 5′ UTR and tested its expression in S. pyogenes (Figure 2. B, PsagA-fflux). 
Unexpectedly, Δrny and WT strains showed similar expression levels for these 
constructs in both ML and ES growth phases (Figure 2. B). It is possible that the 
reporter system does not recapitulate the natural regulation due to plasmid copy 
number or other artefacts.  
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Figure 2. Hemolytic activity is reduced in Δrny compared to the WT strain. Activity of reporter 
fusions containing either the PsagA promoter A) or Δ5′ UTR sagA under the P23 constitutive promoter 
B) in WT (blue bars) and Δrny (orange bars) cultured until ML or ES growth phases. Luminescence 
intensity was normalized against the control plasmid (pEC2174, containing the P23 constitutive 
promoter). Bars show averages for at least three independent biological replicates, error bars 
represent standard deviations. Streptolysin S (SLS)−dependent hemolytic activity of  WT, Δrny and 
Δrny::rny and Δ5′ UTR sagA in ML (C) and ES (D) growth phases. ΔsagA was used as a control. The 
average of three independent biological replicates as percentage of the activity of the WT strain is 
shown. Error bars indicate standard deviation. Independent t−test p values are indicated for relevant 
comparisons: n.s = p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01. 
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RNase Y deletion affects hemolysis in ML but not in ES growth phase 
It is clear that the deletion of RNase Y has a negative effect on sagA transcript 
abundance. In order to test whether RNase Y regulation of sagA transcript has an 
impact in SagA production, we cloned sagA fused to a Flag tag in a plasmid. However, 
after several attempts, no signal was detected corresponding to an expressed SagA-
Flag in S. pyogenes WT and ΔsagA strains containing this recombinant plasmid by 
Western Blot (data not shown).  
As an indirect approach to detect SagA production, we measured the hemolytic 
activity of Δrny and WT. As expected, the hemolytic activity of Δrny cultures in ML 
growth phase was significantly lower when compared to WT or Δrny::rny strains 
(Figure 2. C). Surprisingly, no difference was observed when the hemolysis assay was 
carried out using cultures in ES growth phase (Figure 2. D). Because transcript 
expression is lower in the absence of RNase Y in both growth phases, these results 
indicate that SLS production is uncoupled from transcript abundance, suggesting that 
there are additional mechanisms regulating SLS production. In contrast, hemolytic 
levels were lower in the Δ5′ UTR sagA compared to the WT strain, in both growth 
phases (Figure 2. C-D), indicating that lower transcript levels are not always 
compensated by other processes.  
Further experiments are needed in order to understand the contribution of 
RNase Y to the transcriptional and post-transcriptional regulation of sagA expression. 
Nevertheless, RNase Y seems to affect the sagA transcript by two potentially 
independent mechanisms i) inducing the production of a sRNA from the 5′ UTR of the 
sagA transcript, ii) upregulating sagA transcription through an unknown intermediate 
factor.  
 
Truncations of sagA 5′ UTR affect sagA expression levels  
As shown above, the sagA 5′ UTR is required for WT-levels of sagA expression and 
SLS production. In order to investigate the regions (and structures) that are important 
for SagA production, we generated reporter fusions containing various truncations on 
the 5′ end of the sagA transcript (Figure 3. A). The expression of the truncated fusions 
was evaluated using the mVenus fluorescent protein as reporter in E. coli (Figure 3. B-
D).  
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A first set of translational (TL) fusions included, in addition to the 5′ UTR 
fragment, the first 54 nt of the sagA coding region in frame with the mVenus-coding 
gene (Figure 3. B). Fusions were named TL−S+s, where S and s are the start and stop 
coordinates (from the start codon), respectively. The fusion TL−109+54 (lacking the 
first 35 nt) was expressed at levels similar to those of the full-length fusion 
(TL−144+54). Interestingly, deleting 28 and 43 additional nt (TL−81+54 and TL−66+54) 
caused a reduction in fluorescence of approximately 50% and 80%, respectively, when 
compared to the longer fusions (Figure 3. B). However, removing 39 additional nt 
(TL−27+54) increased the expression to ~40 % of the TL−81+54 truncation (Figure 3. 
B). These results suggest that the integrity of the region downstream of position −109 
of the 5′ UTR is important for sagA expression.  
In order to test whether the first codons of sagA were involved in the repression 
of the shorter truncations, we removed the CDS on the above-mentioned fusions. 
Similar to first set, the fusion starting at position −66 (TL−66+3) showed lower 
expression levels (Figure 3. C). However, all truncations were expressed at higher 
levels (relative to the longest fusion) than constructs containing the sagA CDS 
fragment. In addition, the shortest fusion (TL−27+3) had similar expression levels that 
the longest one (Figure 3. C). Together, these results indicate that the absence of the 
region between −81 and −27 has a negative effect on sagA expression, regardless of 
the presence or absence of the first 18 codons of sagA CDS.  
To determine whether the repression observed in the shorter truncations was 
due to inhibition of translation, we constructed a set of transcriptional (TX) fusions 
containing the same regions of sagA 5′ UTR as in the TL fusions. In these fusions, 
translation of the reporter gene and the fragment of sagA CDS are driven by two 
independent RBSs. Therefore, any effect can be mostly attributed to changes in 
transcript levels (Figure 3. D). Similar to the results of the translational fusions, 
constructs starting at positions −81 and −66 of sagA 5′ UTR had a lower expression 
than the ones with the full-length 5′ UTR. However, the differences in the expression 
of the transcriptional fusions are smaller than in the translational fusions and no 
difference was observed between the fusions starting at positions −81, −66 and −27. 
These results indicate that the truncation of 5′ UTR may have an effect on RNA 
transcription and/or stability.  
In order to confirm the importance of the sagA 5′ UTR, we tested the expression 
of a similar set of fusions in S. pyogenes using the firefly luciferase gene as a reporter. 
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In agreement with the results from E. coli, the expression of the translational (Figure 
3. E) and transcriptional (Figure 3. F) fusions drastically decreased in the fusions 
lacking 76 nt of the 5′ UTR as compared to the full-length or TX−27+54. Moreover, 
quantitative reverse-transcription PCR (qRT-PCR) analysis showed that the RNA 
abundance of TX−66+54 was lower than the full-length and TX−27+54 fusions (Figure 
3. G). In contrast to the nearly 90% loss in luminescence (Figure 3. F), RNA abundance 
of the fusion TX−66+54 was 50% lower than for the full-length fusion (Figure 3. G). 
Furthermore, RNA levels of TX−27+54 were similar to the full-length fusion (Figure 3. 
G). The discrepancies between the luciferase activity and the RNA levels might 
indicate that, at least part of the effect, was due to a reduction of translation. Indeed, 
even if translation of the reporter gene was driven by a separate RBS, the local 
ribosome concentration might be affected by the proximity of the sagA RBS.  
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Figure 3. Truncations of sagA 5′ UTR affect sagA expression levels A) Schematic of reporter 
fusions containing different fragments of sagA 5′ UTR. sagA CDS is colored red and the 5′ UTR and 
RBS are colored blue and green, respectively. B and C) Expression of translational reporter fusions 
under the arabinose inducible promoter (Para) in E. coli containing fragments of sagA 5′ UTR with (B) 
or without (C) the first 54 nt of sagA CDS. D) Expression of transcriptional fusions in E. coli (similar to 
B but the translation of mVenus is driven by a separate RBS). Expression of translational (E) or 
transcriptional (F) reporter constructs containing truncations of sagA 5′ UTR fused to the firefly 
luciferase gene (Luc) under the P23 constitutive promoter in S. pyogenes. G) Relative RNA abundance 
analyzed by qRT−PCR in S. pyogenes. In all plots, the labels in the Y−axis indicates the name of the 
tested fusion. TX and TL are transcriptional and translational fusions, respectively. The numbers 
indicate the coordinates of the start and end of the sagA sequence counting from the sagA start codon. 
Independent t−test p values are indicated for relevant comparisons: n.s = p > 0.05, * = p ≤ 0.05, ** = 
p ≤ 0.01. The schematic on top of each plot indicates the main features of the tested fusion: fragment 
of sagA CDS (red), reporter gene and configuration (transcriptional or translational). Bars represent 
the average of at least three biological replicates relative to the empty reporter vector (fluorescence 
or luminescence intensity) or the longest fusion (qRT− PCR).  
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Structure changes in truncations might inhibit sagA expression 
As shown above, the sagA 5′ UTR gives rise to an sRNA expressed in a growth phase-
dependent manner, suggesting that it is the result of a regulated process. In addition, 
sagA transcript levels are uncoupled from the hemolytic activity (Figure 2.  A and B). 
These results could be explained by changes in RNA structure that regulates 
translation and/or processing.  
Interestingly, structure predictions suggest that the RBS is partially buried in a 
hairpin (Figure 5. A). In addition, this RBS-blocking structure was predicted to occur 
with a higher probability in the fusion with impaired expression (starting at position −66) 
than in fusions showing higher expression levels (Figure 4. B). Furthermore, 
introducing substitutions that were predicted to stabilize the RBS-blocking structure 
(Figure 4. A and C) drastically reduced the expression of all fusions, independently of 
the 5′ UTR fragment that was present (Figure 4. D). However, a set of fusions designed 
to destabilize the structure, with substitutions in predicted base pairs, (Figure 4. C) 
failed to abrogate the reduction in expression caused by the truncation of the 5′ UTR 
(Figure 4. D). This is perhaps due to alternative inhibitory structures formed 
downstream of the RBS (Figure 4. C).  
 Analyses of fusions containing additional mutations in the 5′ UTR suggested 
that the region around position −20 was important for sagA expression. Deletion of 
nucleotides −29 to −20 or −24 to −20, but not deletion of nucleotides −29 to −25, 
inhibited the luciferase expression to the levels of the fusion that starts at position −27 
(Figure 4. A and E). Interestingly, the deletion constructs exhibiting a lower expression 
were also predicted to have a higher probability of forming an RBS-blocking structure 
(Figure 4. E). Together, these results suggest that changes in the structure of the 5′ 
UTR can alter sagA expression. 
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Figure 4. Truncations in sagA 5′ UTR affect the structure of the RNA. A) Schematic representation 
of deletions/substitutions introduced in fusions containing sagA 5′ UTR. Numbers indicate coordinates 
relative to the sagA start codon. Green and red letters indicate substitutions introduced to generate 
the ‘open’ and ‘close’ structures, respectively (see panel C). sagA CDS is colored red, the RBS and 
putative anti−RBS are highlighted in green and yellow, respectively. The UTR is colored blue. B) RNA 
structure prediction of the full−length 5′ UTR (left panel) or truncations (middle and right panels). C) 
Structure predictions of the ‘open’ and ‘close’ mutants, expression of these mutants is shown in D. D) 
Expression of  translational fusions containing different fragments of sagA 5′ UTR with substitutions 
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that are predicted to generate an Open or Close structure (see C). E) Expression of translational 
fusions containing deletions of sagA 5′ UTR as indicated (see panel A). F) Structure prediction of the 
fusions used in E are shown. All structures were predicted using RNAfold web server (Hofacker et al., 
1994) and visualized with varna applet. Color−code indicates the probability associated with the 
position of each nucleotide (red and blue for high and low probabilities, respectively).  
 
Exposure to metabolite mixes affect the sagA 5′ UTR structure 
As shown above, structure prediction of the full-length 5′ UTR and truncations indicate 
that a putative RBS/anti-RBS structure may prevent ribosome binding (Figure 4. A-B). 
Stabilization/destabilization of this putative RBS-blocking structure might play a role in 
regulating sagA translation, potentially explaining the discrepancy between transcript 
abundance and hemolytic activity (Figure 2.  A and B). The presence of a riboswitch in 
the sagA 5′ UTR could provide a mechanism to regulate accessibility of the RBS and 
cleavage of the transcript. Indeed, riboswitches control transcript processing and 
ribosome accessibility, simultaneously (Caron et al., 2012; Shahbabian et al., 2009).  
 To test the possibility that sagA is under the control of a riboswitch, we used a 
reporter fusion that contained sagA 5′ UTR and 18 codons of the CDS fused to the 
gene of mVenus under an inducible promoter. E. coli grown in rich media (EMEM, 
RPMi or LB) showed a small but reproducible reduction in fluorescence intensity 
(relative to the vector lacking sagA 5′ UTR) compared with E. coli grown in minimal 
media (M9, Figure 5. A). This suggested that sagA expression might be inhibited by a 
molecule present in rich media or a secondary metabolite produced under these 
conditions. Furthermore, chemical and enzymatic probing of sagA 5′ UTR showed that 
it adopts a stable secondary structure that could act as a riboswitch or another cis-
regulatory element (Figure 5. B-C). 
 Next, we aimed to determine whether the structure of the 5′ UTR changes in 
vitro in response to binding of a small molecule. For this, we incubated the in vitro-
transcribed sagA 5′ UTR with different concentrations of yeast extract (YE) and 
assessed whether specific changes in structure occurred. YE was used as a source of 
metabolites because most known riboswitches sense molecules that are ubiquitous in 
nature (Lotz and Suess, 2018) and it has been used before successfully for this 
purpose (Nelson et al., 2013). In order to detect any changes in the structure of the 
RNA, we used in-line probing (for a description of the technique see introduction, 
(Regulski and Breaker, 2008). YE caused a concentration-dependent structure change 
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on the sagA 5′ UTR (Figure 5. D), suggesting that a component in the YE induced a 
specific conformational change.  
 It is known that Mg2+ is involved in the stabilization of certain RNA structures 
(Palma et al., 2014). However, a change in structure was still observed upon addition 
of YE in the absence of Mg2+ (Figure 5. E), indicating that Mg2+ is not strictly necessary 
for this YE-dependent conformational change to occur. Additionally, the effect of YE 
was more evident in absence of Mg2+. For these reasons, successive experiments 
were carried out in the absence of Mg2+.  
One of the proposed functions of SLS-mediated hemolysis is to increase iron 
availability (Molloy et al., 2011). To determine whether iron was responsible for the 
observed conformational change, we performed in-line probing in the presence of YE 
and increasing concentrations of ethylenediaminetetraacetic acid (EDTA), which is a 
known divalent ion chelator (Figure 5. E). Despite the fact that EDTA inhibited the effect 
of YE, addition of iron or other divalent cations (in the absence of YE) did not cause 
specific conformational changes (data not shown, summarized in table 1). Moreover, 
the effect of YE on the structure of sagA 5′ UTR was reduced when the extract was 
exposed to high temperatures, indicating that the responsible molecule is heat-
sensitive (Figure 5. D). This led us to the conclusion that the structural change is not 
due to the binding of an ion (Figure 5. F).  
In order to identify the putative ligand, we performed subsequent (high-
performance liquid chromatography) HPLC/in-line probing cycles (in collaboration with 
the Chemical Biology Department at HZI, Braunschweig). After each in-line probing 
experiment, the fraction that caused the conformational change was further separated 
and re-tested (Figure 5. F). The composition and complexity of the fractions was 
monitored after each cycle by mass spectrometry and promising candidates were 
selected for individual testing. Interestingly, a reduced number of fractions for each 
cycle affected the structure of the RNA, suggesting that the structural change was 
specific and only caused by a limited number of molecules.  
Due to the high complexity of the yeast extract, the identification of potential 
ligands was challenging. In order to simplify the analysis, a less complex and partially 
characterized metabolite library from Pseudomonas aeruginosa was used. Both 
P. aeruginosa cell extract and secreted molecules, in addition to one of the active yeast 
extract fractions, caused a similar cleavage pattern in a concentration-dependent 
manner (Figure 5. G). Although several candidates were identified by mass 
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spectrometry analysis, all tested molecules failed to reproduce the pattern caused by 
yeast and P. aeruginosa extracts (data not shown, see Table 1). This may be due to 
the fact that the ligand concentration, while still being able to promote RNA structure 
rearrangements, fell below the limit of detection of mass spectrometry after the HPLC 
fractionation. A list of the tested compounds can be found in Table 1. These results 
suggested that the sagA 5′ UTR changes confirmation to a distinct structure in 
response to the presence of a limited number of metabolites. Future experiments 
should focus on investigating whether these changes translate into regulation of sagA.  
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Figure 5. Exposure to metabolites affects the sagA 5′ UTR structure. A) Expression of sagA 5′ 
UTR translational fusion to mVenus reporter gene in E. coli grown in different media. Fluorescence is 
normalized against the construct without sagA 5′ UTR (pEC2101). Each dot represents an 
independent biological replicate, bars show the average of these replicates and error bars represent 
the standard deviation. Independent t−test p values are indicated by *: *** = p ≤ 0.001, * = p ≤ 0.05.  
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B) Predicted RNA structure of sagA 5′ UTR using RNAfold web server. Numbers indicate coordinates 
from the start codon. sagA CDS is represented by the red arrow. The RBS is highlighted in green. 
Nucleotides highlighted in red and blue show increased and decreased cleavage by in line probing 
(see panels D and E), respectively. Grey squares indicate double−stranded regions according to the 
structure−probing experiment (see panel C). C−G) Structure and in−line probing experiments. Control 
lanes contain the undigested RNA (no reaction, NR), digested with RNase T1 (T1, that cleaves after 
every single−stranded G) or alkaline digestion (−OH, resulting in cleavage in every position along the 
RNA). C) Structure probing of sagA 5′ UTR. Treatment of the RNA with Pb2+ or RNase T1 that 
preferentially promotes cleavage of single−stranded regions, protected regions suggest a stable 
secondary structure (marked with black lines). D and E) Effect of increasing concentrations of yeast 
extract (YE) on the structure of sagA 5′ UTR RNA. Lanes marked with a − show the cleavage pattern 
in the absence of metabolites. Changes in the cleavage pattern after addition YE indicate that one or 
more components of metabolite mixes alter RNA structure. Regions that show increased or decreased 
cleavage rates are marked with red or blue vertical lines, respectively (also indicated in the predicted 
structure on A). E) Addition of YE affects RNA in the presence or absence of Mg2+. EDTA inhibits the 
effect of YE on the structure of the RNA. F) Effect of YE fractions produced by reverse phase 
chromatography (RPC) on RNA structure. Two fractions (5 and 6 containing approximately 50−60% 
acetonitrile) recapitulate the effect of the complete YE. Autoclaved YE does not induce structure 
changes. G) Pseudomonas aeruginosa secreted metabolites (P. S/N), P. aeruginosa cell extract (P. 
extract) or fraction 5 of RPC (YE5) produce a similar pattern than the complete extract in a 
concentration−dependent manner. The lane marked as ACN contains 100% acetonitrile, the solvent 
used for the RPC. RPC was done in collaboration with Franke Raimo and Ulrike Beutling in the 
Chemical Biology department at the Helmholtz Centre for Infection Research, Braunschweig, 
Germany.  
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Table 1: Tested molecules in in-line probing of sagA 5′ UTR 
Class Molecules  
Concentration 
(mM) 
Effect 
Metal Ions 
Fe+2, Fe+3, Zn+2, Co+2, Cu+2, Ni+2, 
Mn+2, Mg+2 
1  
None or  
unspecific degradation 
Quorum 
sensing 
HHQ, DMQ, PQS 4, 0.4, 0.04 None 
Cholate 
derivatives 
Glycocholate, 
Chenodeoxycholate, 
Tauroglycocholate, 
Deoxycholate Methylester, 
Taurolithocholat−derivative 
 
0.03−0.05 None or 
 unspecific effect 
HHQ = 4−hydroxy−2−heptylquinoline 
PQS = 2−heptyl−3,4−dihydroxyquinoline 
DMQ = 2−Polyprenyl−3−methyl−6−methoxy−1,4−benzoquinone 
 
High-throughput method for riboswitch ligand identification 
In-line probing has several limitations as a method to screen for unknown riboswitch 
ligands. First, the fact that it is labour-intensive and low-throughput limits the number 
of molecules that can be tested. Second, the changes in RNA structure do not provide 
information about their biological relevance. Finally, it does not recapitulate kinetic 
processes that can affect riboswitch activity, such as co-transcriptional folding 
(Chauvier et al., 2017). Therefore, we aimed to develop a new method that overcomes 
these limitations allowing us to screen for the putative ligand of sagA 5′ UTR and other 
potential riboswitches. 
To this end, we first constructed plasmids that expressed a bicistronic transcript 
with the mCherry fluorescent protein on the first ORF (open reading frame), and a 
fusion consisting of the riboswitch of interest in frame with the mVenus-coding gene 
on the second ORF (Figure 6. A). mCherry served as a control for any riboswitch-
independent effect of the metabolites on transcription/translation, while mVenus 
fluorescence was used to evaluate the activity of the riboswitch. The expression of 
these fusions was tested in E. coli or using in vitro-transcription/translation (TL/TX) 
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reactions exposed to increasing concentrations of the ligand. In order to test the 
system, we used the predicted thiamine pyrophosphate (TPP) riboswitch from S. 
pyogenes (see below: bioinformatic analysis of riboswitches in S. pyogenes). However, 
no difference in fluorescence was observed in response to addition of TPP either in 
vitro or in E. coli (data not shown). The absence of regulation by the TPP riboswitch 
could be explained by the fact that it was not located at the 5′ end of the transcript, 
making it unable to adopt a native conformation.   
 In order to address this issue, the control and test constructs, encoding the 
mVenus reporter in both cases, were expressed independently under the T7 promoter 
(Figure 6. B). Nonetheless, increasing concentrations of the ligand failed to modulate 
reporter gene expression, both in vitro and in E. coli (data not shown). We hypothesize 
that expressing the riboswitches using the phage T7 polymerase, which has higher 
transcription rates than bacterial polymerases, might decrease the sensitivity of certain 
riboswitches to their ligand. Indeed, transcription speed and pausing has been shown 
to affect the folding of riboswitches (Chauvier et al., 2017). For this reason, we 
exchanged the T7 promoter for the bacterial PLac promoter in the constructs (Figure 
6. B). In this setting, the expression of the fusion that contains the TPP riboswitch 
decreased as the concentration of TPP increases (Figure 6. C), while this trend was 
not observed for the control (Figure 6. D). To account for the unspecific effects of the 
ligand, we calculated the ratio of the expression between the test and the control 
(Figure 6. E). However, although a negative trend in the ratio could be observed with 
increasing concentrations of TPP, the differences were not statistically significant due 
to the high variability of the results (Figure 6. E). Nonetheless, increasing TPP 
concentrations correlated with a decrease in the expression of the test but not the 
control fusions (Figure 6. F-G), indicating that the TPP riboswitch from S. pyogenes is 
able to sense TPP.  
The discovery of new riboswitch ligands would potentially involve testing 
thousands of different molecules. The current method requires testing several ligand 
concentrations in multiple replicates in order to obtain meaningful correlations. Thus, 
further optimization will reduce the number of replicates that are needed to evaluate 
the activity of a riboswitch. Yet, these results indicate that the method developed here 
can be used for verifying whether a predicted riboswitch is functional or testing a small 
number of potential ligands.  
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Figure 6. Method for validating riboswitches in vitro. A) Reporter construct to test the activity of 
riboswitches. Bicistronic operon expressed under the T7 promoter encoding the mCherry fluorescent 
protein as a control (red), followed by a (putative) riboswitch fused to mVenus reporter gene (green). 
B) Independent monocistronic constructs coding for mVenus (green) under the PLac or T7 promoter. 
The test constructs (top) encode the putative riboswitch fused to the mVenus gene. The control 
construct (bottom) encodes only the reporter gene. In all cases, the riboswitches constructs included 
the first 10 to 18 codons of their native downstream gene fused in frame to the reporter gene. C and 
D) Representative fluorescence intensity curves over time of an in vitro transcription/translation 
experiment using construct containing the predicted TPP riboswitch of S. pyogenes (C) or the control 
(D). The blue-color gradient indicates the TPP concentration in the reaction from higher (Dark blue, 
100 μM) to lower (Light blue, no TPP). E) Normalized maximum fluorescence intensity ratio 
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(test/(control+test)) of experiments as in (C and D). Bars indicate the average of six individual 
experiments, error bars represent the standard deviation. F and G) Correlation between ligand 
concentration and expression of the TPP test (F) or control (F) fusions. The dots represent normalized 
end-point fluorescence measurements at different TPP concentrations. The line shows a linear 
regression for these points. Fluorescence of the TPP-test construct in negatively correlated with the 
concentration of TPP (r=-0.58) whereas the control fusion is not (r=0.23). 
 
Analysis of predicted riboswitches in S. pyogenes 
The Rfam database (Kalvari et al., 2017, 2018) lists five riboswitches encoded in the 
genome of S. pyogenes (Table 2). To date, only the glycine riboswitch has been 
experimentally validated (Khani et al., 2018). Therefore, we used the fluorescence in 
vitro TX/TL method to investigate whether the remaining riboswitches respond to their 
predicted ligand.  
 
Bioinformatics analysis of riboswitches in S. pyogenes.  
It was shown that single-nucleotide substitutions in the ligand-sensing motif are 
enough to modify the specificity of riboswitches (Weinberg et al., 2017). Hence, we 
first investigated whether the predicted riboswitches of S. pyogenes deviated from the 
consensus sequence, which would potentially indicate changes in specificity and/or 
functionality. To this end, we aligned the sequence of each predicted riboswitch in S. 
pyogenes to the Rfam consensus and identified the deviating nucleotides (Figure 7. 
A). The high sequence conservation as well as the conservation of base pairs 
suggested that these predicted riboswitches are functional and sense the predicted 
ligand (Figure 7. A).  
 In addition to those predicted by the Rfam database, the presence of two 
additional riboswitches in S. pyogenes was proposed, yybP-ykoY and metk2 (Perez et 
al., 2009; Rhun et al., 2016). The yybP-ykoY has been reported to sense Mn2+ in other 
organisms and its structure in the bound state has been solved (Price et al., 2015). 
Although its sequence in S. pyogenes deviated significantly from the Rfam consensus, 
the conservation of nucleotides known to interact with Mn2+ (Price et al., 2015) 
suggests that its function is preserved. The 5′ UTR of the metk2 gene, which codes for 
the S-adenosylmethionine (SAM) synthase 2, has been suggested to contain a SAM-
sensing riboswitch (Perez et al., 2009). However, sequence and structure prediction 
analyses suggest that it does not belong to any of the five classes of S-
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adenosylmethionine (SAM) riboswitches or of the related metabolite 
S−adenosylhomocysteine (SAH). Consistent with this, the Rfam database did not 
predict the presence of a SAM riboswitch in the chromosome of S. pyogenes and a 
sequence-based search did not render any hits. The number of riboswitch classes 
devoted to sensing SAM suggest that riboswitches have evolved independently more 
than once to monitor the concentrations of this metabolite. Therefore, it is possible that 
the 5′ UTR of metk2 belongs to an uncharacterized riboswitch class. 
To gain insight into the regulatory mechanism used by these seven 
riboswitches, we bioinformatically predicted whether transcriptional terminators or 
RBS-blocking structures are located adjacent to them (Figure 7. B). The predicted 
mode of regulation and location in the genome of the riboswitches are given in the 
table below (Table 2).  
 
Table 2. List of predicted riboswitches in Streptococcus pyogenes  
Riboswitch 
class  
Predicted ligand 
Predicted 
transcriptional 
terminator 
Downstream gene  
(predicted function) 
TPP thiamine pyrophosphate yes thiT (thiamine transporter) 
FMN flavin mononucleotide  yes SPy_0373 (riboflavin transporter) 
glycine glycine no SPy_1270 (amino acid symporter) 
purine guanine no 
xpt (xanthine 
phosphoribosyltransferase) 
preQ1−II pre−queuosine no 
SPy_0749 (citrulline cluster−linked 
gene) 
yybP−ykoY* Mn2+ yes pacL (Ca2+ transporter ATPase) 
metk2* S−adenosylmethionine no 
metk2 (S−adenosylmethionine 
synthase 2) 
Ligand prediction is based on similarity to Rfam consensus. Riboswitches with asterisk (*) are not 
predicted in Rfam of S. pyogenes and ligand is predicted based on genetic context (metk2) or 
similarity to published structures (yybP-ykoY) (Perez et al., 2009; Le Rhun et al., 2016). Intrinsic 
transcriptional terminators were predicted using TransTerm (Kingsford et al., 2007).  
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Functional analysis of predicted riboswitches in S. pyogenes 
Using the fluorescence in vitro TX/TL assay, we confirmed the activity of the TPP, flavin 
mononucleotide (FMN) and Mn2+ riboswitches of S. pyogenes (Figure 7. C). As 
expected, addition of increasing concentrations of the ligand correlated with a 
reduction in fluorescence in the riboswitch-containing fusions but not in the control 
construct (Figure 7. C). Surprisingly, the glycine riboswitch failed to respond to its 
ligand under our experimental conditions. Since the sequence of the glycine aptamer 
in S. pyogenes is conserved (Figure 7. A ), it is possible that the riboswitch is not 
functional under the tested conditions. Indeed, while the concentration used in our 
assay was in the μM range, a recent publication reported that the glycine 
concentrations necessary to elicit a response are in the mM range                      (Khani 
et al., 2018). 
46 
 
 
Figure 7. Functional analysis of predicted riboswitches in S. pyogenes. A) The aptamer column 
shows the sequences of selected riboswitches in S. pyogenes superimposed with the Rfam consensus 
structure for each riboswitch class. Nucleotides that deviate from the sequence consensus are colored 
in green. B) Expression platform column containing the predicted structure (using RNAfold web server) 
of the expression platform of each riboswitch along with the putative regulatory mechanism 
(transcriptional or translational depending on the prediction of a transcriptional terminator or an 
RBS−blocking structure). Start codons are underlined. Color-code indicates the probability associated 
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with the position of each nucleotide (red and blue for high and low probabilities, respectively).  C)  
Response to ligand showing the correlation between ligand concentration and expression of the test 
(green) or control (blue) fusions for each riboswitch. Pearson’s correlation coefficient (r) is indicated for 
each correlation. The line shows the linear regression of at least 3 independent replicates for each 
concentration. The Pearson’s correlation coefficient (r) is shown.  
 
Discussion 
The aim of this study was to investigate the regulation of sagA and its effect in the 
production of SLS. Here, we report that RNase Y has two independent effects on sagA: 
i) it modulates the production of a sRNA that arises from the 5′ UTR of the sagA 
transcript, ii) it upregulates transcription through an unknown intermediate factor. The 
mechanism by which RNase Y gives rise to the sRNA remains unknown. It is likely that 
other factors act together with RNase Y in order to produce a transcript of the observed 
size (approx. 120 nt). Indeed, if RNase Y directly cleaved at the 3′ end of the sRNA, 
mutations in this region would abrogate its production. Since this approach has been 
successful in abrogating RNase Y activity on another target (Broglia et al. 2018), this 
suggests that RNase Y does not cleave in this region of sagA 5′ UTR. In addition, 
preliminary results suggest that the sRNA is produced from the P23-5′ UTR in the WT 
and the Δrny strains, albeit the abundance of the sRNA is lower in the latter. The fact 
that sRNA expression is observed in the Δrny when it is produced from the fusion, but 
not from the chromosome, can be explained by the higher abundance of the transcript 
when it is expressed from a plasmid (Figure 1. E), making the sRNA visible even in the 
production rate is lower. 
Three hypotheses could explain these observations (Figure 8). 1) The sRNA is 
produced by premature transcriptional termination of the sagA 5′ UTR in a process that 
is modulated by RNase Y. 2). A cleavage is produced at the observed 3′ end of the 
sRNA by an unknown RNase that is regulated by RNase Y and has different 
requirements than RNase Y, followed by complete degradation of the 3′ fragment. 3) 
RNase Y cleaves downstream of this region and the sRNA is produced by further 
trimming by a 3′-5′ exoRNase that stops at this position. These three hypothetical 
mechanisms would explain the fact that the fragment downstream of the sRNA is 
undetectable, and that we were unable to inhibit RNase Y cleavage. Further 
experiments are needed in order to determine whether any of the proposed hypothesis 
are correct. In the ES growth phase, the lack of detection of the sRNA might indicate 
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that the sRNA is not produced or that it is unstable. This also suggests that it might be 
produced by a regulated process. It is currently unclear whether the process that 
generates the sRNA has any effect on SLS production, as deletion of RNase Y did not 
have any effect on the expression of the P23-5′ UTR. The high stability of the sagA 
primary transcript and the low abundance of the sRNA suggests the rate at which it is 
produced is low, explaining the lack of regulation. If the mechanism that generates the 
sRNA does not give rise to a stable 3′ fragment, the production of the sRNA can only 
cause a reduction in transcript abundance. On the other hand, if the sRNA is produced 
by a cleavage in the 5′ UTR that produces a stable 3′ fragment, under certain 
conditions, this might modulate translation or stability of the downstream fragment. 
Since we could not detect the 3′ fragment, this latter scenario is unlikely. 
Under the studied conditions, the only regulatory activity of RNase Y on sagA is 
transcription induction. Since RNase Y is not able to regulate transcription directly, one 
or multiple intermediary factors must exist. A transcriptional reporter fusion was 
constructed to investigate the regions upstream of sagA that are involved in RNase Y-
mediated regulation. Because the binding sites for some sagA regulators are known, 
this information might narrow down the number of possible regulators. Unexpectedly, 
the reporter fusion containing the complete intergenic region upstream of sagA was 
not regulated by RNase Y. Introducing the fusion in a plasmid means that there are 
multiple copies of sagA regulatory region per cell. If the number of regulatory molecules 
is limiting, this would reduce the amount of molecules that are bound to the regulatory 
region, abrogating the regulation. Introducing the reporter fusions in a low-copy 
plasmid or in the chromosome will likely address this limitation. Future experiments will 
focus on the identification of the DNA regions that are essential for sagA regulation 
and the regulator that mediates this effect. Differential expression analysis of Δrny 
compared to WT will provide a list of potential regulators. The upregulation of 
sagA mRNA by RNase Y is only physiologically relevant if it affects the production of 
SLS. Interestingly, the hemolysis assay shows that the reduction of sagA transcript 
levels does not automatically entail a lower hemolytic activity, as observed in the ES 
growth phase. sagA transcription is the first of multiple steps in the production of SLS. 
An increase in the rate of any process from SagA translation to its modification and 
export, might compensate for the lower transcript abundance. Although more 
experiments are needed to confirm this hypothesis, there are some pieces of evidence 
that point to a regulation of sagA translation: 1) RNA structure predictions suggest the 
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presence of an RBS blocking structure (Figure 4A), 2) introducing point-mutations or 
deletions that are predicted to stabilize this structure inhibits expression of the reporter 
genes (Figure 4C-F).  
We have shown that truncations of sagA 5′ UTR have a negative effect in 
transcript abundance. However, there is evidence to support that at least part of the 
effect on the production of the reporter proteins comes from translation inhibition. First, 
the reduction of expression detected by qRT-PCR is lower than the effect on 
luminescence in S. pyogenes. Second, the effect of the truncations is less marked in 
the transcriptional than in the translational fusions. It remains to be studied whether 
the reduction in translation affects transcript stability by reducing the number of 
ribosomes exposing it to RNases. Alternatively, removing the 5′ UTR might affect 
transcript stability directly by generating an RNA structure that is permissive to 
cleavage by endoRNases. In addition, removing secondary structures from the 5′ UTR 
end might allow the 5′-to-3′ exoRNase J1 to degrade the transcript. However, it is 
unlikely that this accounts for the whole effect given that it is also observed in E. coli, 
which does not seem to encode 5′-to-3′ RNases. 
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Figure 8. Summary of the effects that RNase Y has on sagA at the transcriptional and post-
transcriptional levels. At the transcriptional level, RNase Y activates PsagA indirectly through an 
unknown factor (represented by the ‘?’) in both mid-logarithmic and early stationary growth phases. 
At the post-transcriptional level, sagA 5′ UTR gives rise to a sRNA that is detectable at mid-logarithmic 
but not early stationary growth phases. Three hypothetical mechanisms may lead to the production 
of a sRNA of the detected size. 1) Transcriptional termination modulated by RNase Y indirectly by an 
unknown factor (represented by the X). 2) RNase Y-regulated cleavage by an unknown RNase (blue 
scissors) at the 5′ UTR followed by degradation of the downstream fragment. 3) Direct RNase Y (grey 
scissors) cleavage downstream of the detected 3′-end followed by degradation by a 3′-to-5′ 
exoRNAse (blue Pacman) until the 3′ end of the sRNA and complete degradation of the downstream 
fragment. At early stationary growth phase, the sRNA might be unstable or not produced. The sagA 
5′ UTR might change secondary structure upon binding an unknown ligand (black circle). The sagA 
promoter is represented by the bent arrow. The sagA 5′ UTR is coloured blue. The RBS is indicated 
with a red rectangle. The red arrow represents sagA CDS and the hairpin represents the attenuator. 
Solid or broken undulated lines represent stable or unstable transcripts.  
 
Modulating accessibility to the RBS would allow for a rapid and reversible regulation 
of sagA translation. The reporter fusion experiments in E. coli show that the presence 
of sagA 5′ UTR upstream a reporter gene makes the fusion sensitive to changes in 
growth conditions. This raises the possibility that the 5′ UTR is able to directly sense 
the presence of a specific molecule and regulate sagA translation. We therefore 
hypothesize that a riboswitch regulates transcription, translation or processing of the 
transcript. In support of this hypothesis, a synthetic transcript that consists of the sagA 
5′ UTR changes conformation when exposed to complex metabolite mixes. Several 
attempts to identify the responsible molecule were unsuccessful. However, the limited 
number of fractions that were able to induce these changes in structure suggests that 
the interaction is specific. It has been proposed that molecules, which interact 
unspecifically with the RNA, appear as a complete or homogeneous degradation 
pattern on in-line probing experiments (Soukup and Breaker, 1999). Yet, whether the 
changes in conformation are functionally relevant remains to be seen.  
In light of the difficulties of identifying the putative ligand of the sagA 5′ UTR, we 
sought to develop a method that allowed us to screen for ligands while providing 
functional information. Detection of fluorescent reporter proteins produced by in vitro 
transcription/translation under the control of a riboswitch allowed us to validate the 
TPP, yybP-ykoY (Mn+2) and FMN riboswitches of S. pyogenes for the first time, proving 
that this method is useful to evaluate the activity of predicted riboswitches.  
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The high variability of the results obtained during the validation of the assay 
meant that the experiment has to be performed using multiple ligand concentrations 
and several replicates to obtain significant correlations. In the current conditions, this 
method can be used to discriminate among a low number of ligand candidates.  
However, further optimization is required in order to use this method to search 
for a ligand in complex metabolite libraries. In an attempt to reduce the variability, a 
construct coding mCherry in a separate plasmid was included in each reaction to 
control for pipetting error. However, this failed to reduce variability across different 
reactions (data not shown). Increasing reaction volumes or using an E. coli extract 
might help reducing errors in future experiments. However, the high costs of the in vitro 
transcription/translation kits are currently limiting the volume and number of reactions 
that can be performed. 
 
Materials and Methods 
Table 3. List of strains used in the study. 
Strain 
name Strain code Relevant characteristics/genotype Source 
Streptococcus pyogenes 
SF370 EC2514  M1 serotype 
ATCC® 
700294TM 
SF370 EC2224  M1 serotype 
ATCC® 
700294TM 
EC2636 EC2514ΔsagA::lox72 Le Rhun unpublished 
EC2641 EC2514ΔsagA5’UTR::lox72 Le Rhun unpublished 
EC2246 EC2224Δrny::lox72 
Broglia et al 
2018 
EC2298 EC2246Δlox72::rny-TT3-lox72 
Broglia et al 
2018 
Escherichia coli 
Top10 RDN204  
E. coli K12 F– mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara-
leu)7697 galU galK λ
– rpsL(StrR) endA1 nupG  
 
Invitrogen 
 
Table 4. List of plasmids used in the study 
Plasmid code Relevant characteristics Source 
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Plasmids for translational fusions of sagA 5’UTR to mVenus (for expression in E. coli) 
pBAD18 pBAD18 (Guzman et al., 1995) 
pEC2101 pBAD18ΩmVenus This study 
pEC2102 pEC2101Ω5’UTRsagA_SagA18codons This study 
pEC2115 pEC2101Ω5’UTRsagA-109_+54 This study 
pEC2116 pEC2101Ω5’UTRsagA-81_+54 This study 
pEC2117 pEC2101Ω5’UTRsagA-66_+54 This study 
pEC2118 pEC2101Ω5’UTRsagA-27_+54 This study 
pEC2126 pEC2101Ω5’UTRsagA-144_+3 This study 
pEC2127 pEC2101Ω5’UTRsagA-109_+3 This study 
pEC2128 pEC2101Ω5’UTRsagA-81_+3 This study 
pEC2129 pEC2101Ω5’UTRsagA-66_+3 This study 
pEC2130 pEC2101Ω5’UTRsagA-27_+3 This study 
Plasmids for transcriptional  fusions of sagA 5’UTR to mVenus in E. coli 
pEC2133 pEC2101Ω5’UTRsagA-144_+54 This study 
pEC2134 pEC2101Ω5’UTRsagA-109_+54 This study 
pEC2135 pEC2101Ω5’UTRsagA-81_+54 This study 
pEC2136 pEC2101Ω5’UTRsagA-66_+54 This study 
pEC2137 pEC2101Ω5’UTRsagA-27_+54 This study 
Plasmid containing sagA 5’UTR with substitutions in putative anti-RBS sequences 
pEC2147 pEC2102-40TGAAA This study 
pEC2148 pEC2115-40TGAAA This study 
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pEC2149 pEC2116-40TGAAA This study 
pEC2150 pEC2117-40TGAAA This study 
pEC2151 pEC2102-40TACCTC This study 
pEC2152 pEC2115-40TACCTC This study 
pEC2153 pEC2116-40TACCTC This study 
pEC2154 pEC2117-40TACCTC This study 
Plasmids for constructing translational reporter fusions to firefly luciferase in S. pyogenes  
pEC2174 pLZ12Km2-P23R:TA:fflucRT 
(Loh and Proft, 
2013) 
pEC2274 pEC2174ΩPsagA This study 
pEC2237 pEC2174ΩsagA-144+54 This study 
pEC2238 pEC2174ΩsagA-66+54 This study 
pEC2239 PEC2174ΩsagA-27+54 This study 
pEC2293 pEC2237-Δ10-29 This study 
pEC2294 pEC2237-Δ5-29 This study 
pEC2295 pEC2237-Δ5-24 This study 
pEC2296 pEC2237-ATG-ATT This study 
pEC2297 pEC2237-116G-A This study 
pEC2298 pEC2237-127G-A This study 
pEC2299 pEC2237-132GG-AA This study 
 
Plasmids for constructing transcriptional reporter fusions to firefly luciferase in S. pyogenes  
pEC2270 pEC2174ΩsagA-144+54 This study 
pEC2271 pEC2174ΩsagA-66+54 This study 
pEC2272 PEC2174ΩsagA-27+54 This study 
pEC2273 pEC2173ΩsagA-144+54 This study 
Plasmids for reporter fusions of putative S. pyogenes riboswitches to mVenus  
(for expression in vitro) 
pET21b-RL027 pET21b-RL027 Lentini et al 2013 
pEC1985 pET21b-RL027ΩmVenus This study 
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pEC2175 pEC1985ΩPlac This study 
pEC2176 pEC2175ΩPlac_SpyTPP+11aa This study 
pEC2177 pEC2175ΩPlac_SpyFMN+14aa This study 
pEC2179 pEC2175ΩPlac_SpyGlycine+13aa This study 
pEC2180 pEC2175ΩPlac_SpyMetk2+10aa This study 
pEC2181 pEC2175ΩPlac_SpyyybP-ykoY+12aa This study 
 
Table 5. List of primers used in the study. 
Primer 
code Target Sequence 5´-3′ F/R
a 
 NBb 
OLEC3273 5´UTR sagA mRNA AGCTCAATTGTACTGTTGTAACA R 
OLEC7883 sagA mRNA TTATTTACCTGGCGTATAACTTCCGC R 
OLEC288 5S rRNA AGTTAAGTGACGATAGCCTAG  F 
OLEC287 5S rRNA CTAAGCGACTACCTTATCTCA  R 
qRT-PCRc 
OLEC8570 fflucRT TAACCAGTCATTTGCCGCCT F 
OLEC8571 fflucRT ACGAGCGTGAGAAAAGCGTA R 
qRT-PCR control 
OLEC8574 RepA TTATTCGCCTTAGGGGAGCG F 
OLEC8575 RepA CCCCCGTTTCAGCATCAAGA R 
Constructing translational fusions of sagA 5’UTR to mVenus in pBAD18  
OLEC3663 
 Xbal_mVenus 
CAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGA
AGGAGATATACATATGAGCAAAGGCGAAGAACTGTT
C 
F 
OLEC3664 mVenus_BamHI CAAACTAATTGAATTCGGATCCGCTTATTTATACAGTTCATCCATACCATGCGTAATGCC R 
OLEC7842 sagA 5’UTR -144 
AAGCGGATCCGAATTCGATAAGAACTAGATAGTTGTT
GTGTTACAACAG F 
OLEC7843 sagA 5’UTR -109 
AAGCGGATCCGAATTCCAATTGAGCTAGCCTTGTCC
TTGTTG F 
OLEC7844 sagA 5’UTR -81 AAGCGGATCCGAATTCTTAACTTTATTTTTAAAATAAGGTTAAAAATAAACGACTCG F 
OLEC7845 sagA 5’UTR -66 AAGCGGATCCGAATTCAAATAAGGTTAAAAATAAACGACTCGCG F 
OLEC7846 sagA 5’UTR -27 AAGCGGATCCGAATTCTACTTATTAGATAAGGAGGTAAACCTTATG F 
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OLEC7383 sagA +54 CGCCTTTGCTCATATGTTGAGTTGTTTCAGCTACACTAGTAGC R
 
Constructing translational fusions of sagA 5’UTR to mVenus in pBAD18 (with OLEC7842 to 78846) 
OLEC7416 sagA CCTTTGCTCATATGTTATTCTCCTTATAAGTTCAAACTAATGAGTTGTTTCAGCTACACTAGTAGCTAA R 
Introducing substitutions in putative anti-RBS sequences 
OLEC8046 sagA 5’UTR  CGACTCGTGAAATTATCAGTTACTTATTAG F 
OLEC8047 sagA 5’UTR  CTGATAATTTCACGAGTCGTTTATTTTTAACC R 
OLEC8048 sagA 5’UTR  CGACTCACCTCCTTATCAGTTACTTATTAG F 
OLEC8049 sagA 5’UTR  CTGATAAGGAGGTGAGTCGTTTATTTTTAACC R 
Constructing translational reporter fusions to firefly luciferase in S. pyogenes   
OLEC8380 sagA 5’UTR -144 
CAGACCTAAGACTGATGACAAAAAGAGAAAATTTTGA
TAAAATAGTCTTAGATAAGAACTAGATAGTTGTTGTG
TTACAACAGTACAATTG 
F 
OLEC8381 sagA 5’UTR -66 
CAGACCTAAGACTGATGACAAAAAGAGAAAATTTTGA
TAAAATAGTCTTAAAATAAGGTTAAAAATAAACGACT
CGCGTTC 
F 
OLEC8382 sagA 5’UTR -27 
CAGACCTAAGACTGATGACAAAAAGAGAAAATTTTGA
TAAAATAGTCTTATACTTATTAGATAAGGAGGTAAAC
CTTATG 
F 
OLEC8383 sagA 5’UTR +54 GGGGCAGGACCTTTCTTGATATTCTTAGCATCTTCCATATGTTGAGTTGTTTCAGCTACACTAGTAG R
 
Constructing transcriptional reporter fusions to firefly luciferase in S. pyogenes   
OLEC7962 sagA 5’UTR +54 ACCTGTGAGAATTCTTATTATTGAGTTGTTTCAGCTACACTAGTAGC R
 
OLEC8576 sagA up 500  CTAGAGCAGAGCTCCTGTGAAGGTGATGGTAGTTCCACC F 
OLEC8577 sagA  ATCACCATCCGCGGCACTTTTATTATAGTAAAAAATGATTAATATGTAAACCCTTTC R 
Constructing  reporter fusions of putative S. pyogenes riboswitches to mVenus (for expression in vitro) 
OLEC3774 Spy_FMN ATAAGCGGATCCGAATTCGTGTCTTCAGGGCAGGGTGTG F 
OLEC3775 Spy_FMN CGCCTTTGCTCATATGAGAAAGTATACCAATCATAATCATTTTATGTGTTTTTGACAT R 
OLEC3776 Spy_Gly ATAAGCGGATCCGAATTCTTAATAAACCGAATGATGTCATGCAGGAGAAG F 
OLEC3777 Spy_Gly CGCCTTTGCTCATATGCCAAACAAGGTTATCAATTAATTTAACGAGTGCTATCAT R 
OLEC3782 Spy_TPP ATAAGCGGATCCGAATTCACTATAATATTTCACAAAGGAGTGCTTTGGCTG F 
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OLEC3783 Spy_TPP CGCCTTTGCTCATATGGATAAGGTATTTGACATTGGTGTTTGGTGAC R 
OLEC3784 Spy_yybP-yko ATAAGCGGATCCGAATTCTCAAGGGAGTAGCAGACGGCTAG F 
OLEC3785 Spy_yybP-ykoY CGCCTTTGCTCATATGCGTGTAAAATGCTTCATGTCTTTGTTCTTTAGAC R 
a F, forward primer; R, reverse primer 
b NB, Northern Blot assay usage 
c qRT-PCR, Quantitative transcription PCR usage 
 
Bacterial strains and growth conditions 
Table 3 describes all the bacterial strains used in this study. E. coli (Top 10) strain was 
used as a host for cloning. It was grown at 37 ºC with shaking in Luria Bertani medium. 
When needed kanamycin antibiotic was added at a final concentration of 25 µg/ml. S. 
pyogenes M1 GAS SF370 (wild type, ATCC 700294) and derivative deletion mutants 
were cultured at 37 ºC without agitation in a 5% CO2 atmosphere. Todd Hewitt broth 
(THY) supplemented with 0.2% yeast extract (Servabacter ®) and plates containing 
tryptic soy agar (TSA) supplemented with 3% sheep blood (Oxoid) were used as liquid 
and solid media, respectively. When required kanamycin antibiotic was added to the 
medium at a final concentration of 300 μg/ml. Bacterial growth was monitored by 
measuring optical density at 620 nm (OD620) with a microplate reader (Eon™, biote ®) 
using 200 µl of culture. All bacterial strains used in this study were stored at -80ºC. 
When needed, they were grown over day on a plate and then overnight in 5 ml of THY 
liquid cultures. For each experiment, 100 ml-flasks containing 50 ml THY were 
inoculated 1:100 with overnight cultures and grown until the desired OD was reached. 
In this study, bacteria were collected in two growth phases: ML (OD620 = 0.25) and ES 
(OD620 = 0.4). 
 
Bacterial transformation  
Plasmids used are listed in Table 4. In order to transform S. pyogenes, 
electrocompetent cells were prepared as in (Caparon and Scott, 1991). Competent 
cells were stored in 20% ice-cold sterile glycerol at -80 ºC. Bacteria were 
electroporated in 100 µl of 20% ice-cold sterile glycerol. The OD620 of the competent 
cells was adjusted to 2 or 3 before adding 150 ng and 210 ng of plasmid in the WT and 
mutant strains (Δrny, ΔsagA), respectively. The cells were electroporated in a 0.1 cm 
electroporation cuvette (Bior) with a pulse of 400 Ω and 25 μF as previously described 
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by (Perez-Casal et al., 1991) with slight modifications. Immediately after transformation 
bacteria were transferred to tubes containing 4 ml of THY and incubated for 2 hours. 
Next, 100 µl of the culture were plated in TSA blood plates supplemented with 
kanamycin. Plates were incubated for 24 hours and single colonies were used to 
inoculate 3 ml overnight cultures. Fresh transformations were used for each 
experiment. 
 
RNA extraction 
25 ml of culture was mixed with 25 ml 1:1 acetone:ethanol (prechilled at -20). Total 
RNA was extracted using TRIzol (Sigma-AldrichTM)/chloroform extraction and 
isopropanol precipitation from samples collected at ML and ES. RNA concentration 
and integrity were determined using an UV-spectrophotometer (NanoDropTM, 
ThermoScientificTM) and agarose gel electrophoresis analysis. 
 
Polyacrylamide Northern blot analysis  
Northern blot analysis was carried as previously described (Fonfara et al., 2014). 
Briefly, total RNA was separated on 10% polyacrylamide gels (8 M urea) for 
approximately 3 h at 100 V and transferred onto nylon membranes (Hybond™ N+, GE 
healthcare) using Trans-Blot® SD semi-dry transfer apparatus (Biorad) for 45 min at 
18 V. The crosslinking was performed using EDC (1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (Sigma) for 1 hour at 60 ºC. Prehybridization was done 
using Rapid-hyb buffer (GE healthcare) for 15 min at 42°C. The hybridization was 
carried out overnight at 42 ºC with the previously 5′ radiolabeled oligonucleotide probe 
(Table 5). The T4-polynucleotide kinase (Fermentas) was used to label 2 µl of (20 
pmol/µl) oligonucleotide probes with 32P (0.75 MBq) according to the manufacturer's 
protocol. The probes were purified with G-25 columns (GE Healthcare). The 
membranes were then washed with washing buffer I (5X Saline-Sodium Citrate (SSC), 
0.1% Sodium dodecyl sulfate (SDS) and then with the washing buffer II (1X SSC, 0.1% 
SDS) for 15 min. Visualization of the radioactive signal was done using a 
phosphorimager FLA-9500 (GE HealthCare) after approximately 5 days of exposure. 
The 30-330-bp AFLP ® DNA Ladder (Invitrogen™) was used as a size marker. The 
5S rRNA was used as loading control. The 5S rRNA-specific oligonucleotide probe 
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(Table 5) was hybridized for 1 h and the membrane was washed and exposed as 
before.  
 
Rifampicin assay 
WT and deletion mutant (Δrny and Δ5′ UTR) strains were grown overnight in 10 ml 
THY cultures. The overnight cultures were diluted 1:200 in THY medium and grown 
until ML and ES growth phases. Rifampicin (Sigma-Aldrich) was dissolved in methanol. 
Once cultures reached the desired OD620, the rifampicin was added at a final 
concentration of 250 µg/ml. 25 ml of the culture were harvested at the desired time 
points (0, 30, 60, 90, 120 and 150 min) after rifampicin addition. Afterwards RNA 
extraction was done as described previously and analyzed by Northern Blot. 
 
Transcriptional luciferase reporter expression  
The plasmid-based reporter system (pLZ12Km2-P23R:TA:fflucRT, Addgene plasmid 
gift from Thomas Proft) described in (Loh and Proft, 2013) was used to construct 
plasmid pEC2274, in which the expression of ffluc (firefly luciferase gene) is under the 
control of the sagA promoter region (containing 500 bp upstream the start codon).  
 Briefly, pLZ12Km2-P23R:TA:fflucRT was digested with SacI and SacII (Thermo 
Scientific) to remove the lactococcal constitutive promoter P23. PsagA was amplified 
from WT genomic DNA using primers OLEC8576/OLEC8577 and cloned in 
pLZ12Km2-P23R:TA:fflucRT to create plasmid pEC2274. WT and Δrny cells were 
transformed and the activity of sagA promoters was measured. After diluting the 
overnight culture 1:200 in fresh THY, 200 µl of culture per well were added in duplicates 
in a white opaque 96-well microtiter plate with clear flat bottom (Greiner Bio-One TM) 
and incubated in the plate reader (synergy, BioTek) at 37º C with 5 % CO2. Beetle 
luciferin potassium salt (Promega) was added to each well at a final concentration of 
50 ng/μl when the desired OD620 was reached (ML for one of the duplicates and ES for 
the other). Luminescence was measured immediately after luciferin addition using a 
microplate reader (BioTekTM synergy) with an integration time of 1 sec, with a gain of 
120, and a read height of 1 mm. The signal was normalized by dividing it to the signal 
of the control plasmid (pLZ12Km2-P23R:TA:fflucRT) and with the luciferase signal 
obtained from the constitutive promoter P23. The experiments were carried out in 
independent biological triplicates, each with technical duplicates.  
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Hemolysis assay 
The hemolysis assays were performed as previously described by (Loridan and Alouf, 
1986), with modifications. 5 ml defibrinated sheep blood (Oxoid) was washed 3 times 
with 50 ml cold phosphate buffer saline (PBS). Once the strains of interest reached the 
desired growth phase needed, 50 ml of bacterial culture were collected and pelleted at 
4000 rpm for 15 min at 4 ºC.  
Then, bacteria were resuspended in 5 ml PBS for ES and 3 ml PBS for ML. Next, 200 
µl were taken and 3 serial dilutions 1:1 were done with PBS in a flat-bottom 96-well 
plate. After, 50 µl of the bacterial dilutions were transferred to a round-bottom 96-well 
plate containing 50 µl of the washed blood per well. PBS or Triton 1% was added 
instead of bacteria as negative and positive controls, respectively. Plates were 
incubated for 1 h at 37 ºC, and subsequently centrifuged for 15 min at 400 x g at 4 ºC. 
In order to measure hemoglobin content, 50 µl of the supernatant were collected 
diluted 1:1 in PBS and transferred in a new 96-well flat-bottom plate to measure 
absorbance at 540 nm. Serial 1:1 dilutions were made with PBS until values were 
within readable ranges. To ensure that the hemolysis assay was not saturated, 
bacterial dilutions where any of the strains reached 100 % lysis (similar to the well with 
triton) were disregarded. The dilution with the highest bacterial concentration that was 
not saturated was used for each experiment. The measurements were then normalized 
against the WT strain for each experiment. Technical duplicates and biological 
triplicates were performed for each experiment.  
 
qRT-PCR 
Quantitative real time PCR (qRT-PCR) experiments were performed using total RNA 
extracted from the indicated strains. RNA was treated with DNase I enzyme, using 
TURBO DNA-free™ Kit (Invitrogen), according to the manufacturer's instructions. 
Reactions were performed in 50 µl containing 50 ng/µl of RNA. The absence of DNA 
contamination was corroborated by PCR amplification method (using oligos that target 
the 5S rRNA shown in Table 3). The qRT-PCR was done using the Power SYBR Green 
RNA- to- CT TM 1 Step Kit (applied biosystems) according to the manufacturer's 
instructions in 10 µl reactions using primers (shown in Table 5). In order to get the ideal 
RNA concentration, we performed serial dilutions of the RNA samples adding 1 µl of 
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RNA (0.01 ng/µl) and we add 0.1 µl of each primer (20 ng/µl) per reaction. The rest of 
the compounds were added in the volumes indicated by the protocol. While preparing 
the reactions, we always made common stocks in order to reduce the variability and 
pipetting errors as much as possible, adding 20% more for each reaction. In order to 
prove the specificity of the primers used and their respective targets, amplicons melting 
curve analysis was evaluated. During this assay, we use technical duplicates and the 
same procedure was performed using biological triplicates.   
 
In vitro transcription 
sagA 5′ UTR (as determined by RNAseq) was in vitro-transcribed using Ampliscribe 
T7 Flash transcription kit (epicentre) according to the manufacturer's instructions. The 
template was produced by PCR using primers OLEC5248 and OLEC5249 and 
contained the T7 promoter in addition to the 144 nt upstream sagA start codon. The 
PCR product was gel-purified with the Gel Extraction Kit (Qiagen) prior to use. A 40 µl 
transcription reaction was mixed according to the manufacturer's instructions and 
incubated at 42 ºC for > 3h. Transcript was treated with DNase I (RNase-free NEB) 
and ethanol-precipitated. Precipitated RNA was gel-purified by electrophoresis on a 
10 % polyacrylamide gel with 4 M urea. The gel was stained with ethidium bromide, 
bands were cut and RNA eluted at 50 ºC with eluRNA solution (0.3 M Na acetate, 0.5 
EDTA and 0.1% SDS). Eluted RNA was ethanol-precipitated and stored at -20 ºC. 
 
Labelling and purification 
Before labelling, RNA was dephosphorylated using FastAP™ (Fermentas). Briefly, a 
20 µl reaction containing 1 µM RNA and 1 µl FastAP was incubated at 37 ºC for at 
least 15 min. RNA was purified using RNA clean and concentrator-5 (Zymo Research). 
After, 30 pmol of dephosphorylated RNA was 5′-end-labelled with P32 using PNK 
(Fermentas) for 30 min at 37 ºC. Next, RNA was purified using Illustra MicroSpin G-25 
columns (GE Healthcare), gel-purified and precipitated as before. Finally, RNA was 
resuspended in 60 µl of water and stored at – 20 ºC until used. 
 
RNA structure probing 
To determine the structure of sagA 5′ UTR, the in vitro transcribed RNA was treated 
with either RNase T1 (Ambion), RNase III (Ambion) or lead(II) acetate (Sigma Aldrich). 
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For structure-sensitive RNase T1 or RNase III digestion, 10 µl reactions were prepared 
(according to the manufacturer’s instructions) containing 1 µ labelled RNA, 1 µl 10X 
structure buffer, 1 µg Yeast RNA, 1 µl RNase. Reaction was incubated for 3 min at 37 
ºC and reaction was stopped by adding 10 µl of 2x urea loading buffer (10 M urea, 1.5 
mM EDTA, pH 8). Lead (II) was carried out by mixing 1 µl labelled RNA with 1 µl 
structure buffer, 1 ug yeast RNA, 1 µl Lead acetate 25 mM (freshly prepared) and 6 µl 
H2O. Reaction was incubated for 1 min at 37 ºC and stopped with 10 µl urea loading 
buffer. RNase T1 was also used to generate a ladder under denaturing (structure-
insensitive) conditions by incubating 5 min at 55 ºC the following reaction: 1 µl 10X 
Buffer (0.25 M Na citrate pH 5.0), 7 µl urea loading buffer and 1 µl labelled RNA. The 
reaction was stopped with 3 µl loading buffer and 7 µl H2O. Alkaline (OH) ladder was 
generated by incubating for 10 min at 90 ºC a 10 µl reaction containing: 1 µl labelled 
RNA and 1 µl Na2CO3 10X (0.5 M Na2CO3 pH 9.0, 10 mM EDTA). 
 
In-line probing 
In-line probing experiments were done as previously described (Regulski and Breaker, 
2008). RNA was incubated overnight at 37 ºC in 10 µl reactions containing 1 µl labelled 
RNA and 5 µl 2x reaction buffer (100 mM Tris-HCl pH 8.3, 200 mM KCl with or without 
40 mM MgCl2 as indicated), ions or yeast extract was dissolved in water and added to 
the reaction in the indicated concentrations.  
After incubation reaction, 10 µl urea loading buffer was added and samples were 
resolved by electrophoresis in sequencing 10 % polyacrylamide gel with 8 M urea. The 
gels were finally exposed overnight in a BAS Storage Phosphor Screens (GE 
HealthCare) and developed using a Typhoon FLA 9500 (GE Healthcare). 
 
Reverse phase chromatography 
Yeast extract powder (servabacter) was dissolved in water to 100 mg/ml and 
fractionated by reverse phase chromatography using a Octadecyl Solid Phase 
Extraction Column (JT Baker). 
 
Fluorescent in vitro transcription/translation assay 
In vitro transcription/translation reactions were carried out using the PurExpress kit 
(NEB). Reactions were done in a final volume of 6 µl containing 1.7 µl Solution A, 1.25 
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µl Solution B, 0.04 µl RNasin, 1 µl E. coli RNA polymerase holoenzyme (NEB), 1 µl 
ligand (6x) and 1 µl template plasmid (Table 4). Reaction mixes were prepared for the 
test and control plasmids separately, without the ligand. Then 5 µl of the mix were 
added to each well of a black plate with 148 low volume wells with transparent flat 
bottom. 
 Finally, 1 µl of diluted 6x ligand was added to the mix and fluorescence was 
read in a plate reader. The reaction was carried out at 37 ºC for 10 h and 
measurements were taken every 30 min. Because in these conditions, protein amount 
cannot decrease, any reduction in fluorescence was taken as an artefact. Therefore, 
the maximum fluorescence value for each reaction was taken for further analysis. 
Then, the values from the different experiments were normalized against the highest 
value for each construct. The expression ratio between the test and the control was 
calculated by dividing the normalized value for the test construct by the sum of the test 
and the control. These normalized values were also used to obtain the correlations 
between the ligand concentration and the expression of the construct. The linear 
regression was plotted using python seaborn.lmplot library. The Pearson’s correlation 
coefficient (r) is shown for each regression and was calculated using 
scipy.stats.pearsonr python library. 
 
Contributions 
Anaïs Le Rhun did the the RNAseq analysis and preliminary Northern blot analyses of 
sagA 5′ UTR in WT and Δrny strains. Anne-Laure Lécrivain constructed the rny deletion 
and complemented strains and analyzed the expression profile of RNase Y in different 
growth phases. Victoria Gabriel contributed to the cloning of constructs and performed 
the Northern blots and expression analysis of sagA reporters. HPLC was performed 
by Raimo Franke and Ulrike Beutling from the Chemical Biology Department at the 
Helmholtz Centre for Infection Research, Braunschweig. 
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Chapter Two:  
Regulatory roles of Cas9 in Francisella novicida 
Introduction  
As mentioned in chapter one, a specific class of ncRNAs are part of the CRISPR 
adaptive immune systems. These are present in approximately 87% of archaeal and 
50% of bacterial sequenced genomes (Jackson et al., 2017) and defend prokaryotic 
cells against foreign nucleic acids. CRISPR-Cas systems are commonly composed of 
CRISPR RNAs encoded by the CRISPR array and the CRISPR-associated (Cas) 
proteins. The array contains a variable number of identical repeats interspaced with 
unique sequences, known as spacers. The number and identity of the Cas proteins 
varies across different CRISPR-Cas types.  
Despite the diversity of CRISPR-Cas systems, they all achieve immunity 
through three general stages: 1) Acquisition, also known as adaptation, 2) 
expression/processing and 3) interference (Hille et al., 2018). 
Acquisition occurs when a bacteriophage or a plasmid invades a bacterial cell, 
and part of its genetic material is integrated in the CRISPR array, generating a new 
spacer. Cas1 and Cas2, two Cas proteins found in most CRISPR-Cas systems, are 
involved in spacer acquisition (Makarova et al., 2011, 2015; Nuñez et al., 2014, 2015a, 
2015b). 
This new spacer constitutes a “memory” device that allows identification and 
targeting of the same threat upon reinfection (see below). The expression/processing 
stage consists of transcription of the array, to produce a precursor CRISPR RNA (pre-
crRNA), followed by maturation, which involves the specific cleavage of the pre-crRNA 
to produce various crRNAs. Each mature crRNA is comprised of a repeat (or part of it) 
and a spacer (or part of it). In the final stage, interference, an invading genetic molecule 
containing a complementary sequence to the spacer (protospacer), is recognized and 
digested, preventing its maintenance and replication.  
 The array was first discovered in 1987 (Ishino et al., 1987) and in 2002 
its association with cas genes was first noticed (Jansen et al., 2002). However, the 
function of the array and the Cas proteins remained obscure. In 2005, the homology 
of the spacers to phages and other mobile genetic elements led to the hypothesis that 
CRISPR-Cas constitutes a defense system, which was confirmed in 2007 (Barrangou 
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et al., 2007; Bolotin et al., 2005; Makarova et al., 2006; Mojica et al., 2005). Soon after, 
it was shown that in some types of CRISPR-Cas (types I and III), the crRNAs guide a 
complex of Cas proteins to destroy phages by targeting DNA (Brouns et al., 2008; 
Marraffini and Sontheimer, 2008). 
To date, multiple RNA and DNA-targeting CRISPR-Cas systems have been 
discovered and classified in two classes and six types (Koonin et al., 2017; Makarova 
et al., 2013; Shmakov et al., 2015, 2017). Class 1 includes types I, III and IV, which 
use a complex of multiple Cas proteins to carry out interference. In contrast, class 2 
systems use only one Cas protein in the interference step and is comprised of types 
II, V and VI.  
Because of their simplicity class 2 systems, especially the type II systems, have 
been used for genetic engineering (see below).  
 
Type II CRISPR-Cas systems  
Type II systems, further subdivided in three subtypes (A-C), are DNA-targeting 
systems characterized by the presence of Cas9 and the trans-activating crRNA 
(tracrRNA) (Chylinski et al., 2013; Deltcheva et al., 2011). Type II-A systems contain 
the characteristic csn2 gene (Makarova et al., 2015; Shmakov et al., 2017, Koonin et 
al., 2017), which codes for a protein that is involved in spacer acquisition (Heler et al., 
2015; Ka et al., 2018; Wei et al., 2015). In contrast, type II-B systems lack csn2 but 
encode Cas4, which is also involved in acquisition (Kieper et al., 2018; Lee et al., 2018; 
Shiimori et al., 2018). Type II-C contain only the genes coding for Cas9, Cas1 and 
Cas2. The length and sequence of Cas9 vary from one subtype to another (Chylinski 
et al., 2013). 
tracrRNA contains an anti-repeat sequence that mediates the formation of a 
duplex with the pre-crRNA repeats (Deltcheva et al., 2011). The duplex is promoted 
and stabilized by Cas9. Once the Cas9:tracrRNA:crRNA complex is formed, the duplex 
of RNAs is co-processed by RNase III. Further trimming of the RNAs by unknown 
RNases gives rise to the mature tracrRNA:crRNA duplex, which remains bound to 
Cas9 (Deltcheva et al., 2011). In the type II-C systems of Neisseria meningitidis and 
Campylobacter jejuni, each crRNA is transcribed from their own promoter, located 
within each repeat (Dugar et al., 2013; Zhang et al., 2013). Though RNase III 
processing of the duplex is still observed, this is not required for activity (Zhang et al., 
2013). 
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Binding of Cas9 to tracrRNA:crRNA triggers a conformational change that 
renders Cas9 capable of searching for target protospacers that are complementary to 
the spacer of crRNA (Jinek et al., 2014). In order to avoid targeting the CRISPR array 
in the bacterial chromosome, Cas9 only checks for complementarity in the sequence 
that is next to a PAM. Because the PAM is present next to the protospacer but absent 
in the CRISPR array, this prevents self-targeting by Cas9. The sequence of the PAM 
varies depending of the Cas9 orthologue (e.g. NGG for S. pyogenes Cas9) (Gasiunas 
et al., 2012; Jinek et al., 2012). Upon DNA invasion, Cas9 in complex with the 
tracrRNA:crRNA duplex samples the available PAMs and starts unwinding the DNA 
helix upstream of the PAM in search of a protospacer. Both, the contact with the PAM 
and the spacer-protospacer base-pairing are essential requirements to activate Cas9 
DNA endonuclease activity, which leads to a double-strand break of its target (Jinek et 
al., 2014; Sternberg et al., 2014). Although some mismatches can be tolerated 
between the spacer and the protospacer, a PAM-proximal seed sequence of 10- to 12-
nt must be fully complementary for Cas9 to cleave (Anders et al., 2014; Jiang et al., 
2013; Jinek et al., 2012; Sternberg et al., 2014; Szczelkun et al., 2014). However, 9 
base pairs in the PAM-proximal region are enough for stable binding of Cas9 to the 
DNA (Singh et al., 2016). 
 
Cas9 structure and biochemistry 
Cas9 is a multi-domain protein that contains three conserved features: two nuclease 
domains (HNH and RuvC-like) and an Arg-rich motif. The HNH and the RuvC-like 
domains cleave the complementary and non-complementary strands in the 
protospacer, respectively, producing a double-strand break. Both nuclease domains 
require Mg2+ to cleave DNA (Jinek et al., 2012).  
Cas9 is arranged in two lobes, named the recognition (REC) lobe and the 
nuclease (NUC) lobe. The REC lobe consists of three regions: the bridge helix, the 
REC1 domain and REC2 domains. The NUC lobe contains the RuvC, the HNH and 
the PAM-interacting domain. This latter one determines the PAM specificity. The 
RNA:target DNA complex is enclosed between the REC and the NUC lobes. The Arg-
rich motif, located in the bridge helix, is shown to interact with the spacer (Nishimasu 
et al., 2014). This interaction appears to be sequence-independent, in contrast to the 
repeat:anti-repeat region of the duplex, recognized by the REC lobe, which appears to 
be sequence-specific. Mismatches between the repeat and the anti-repeat that do not 
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alter the structure of the duplex are tolerated (Briner et al., 2014).  
While the arginine residues on the bridge helix are highly conserved in all type 
II CRISPR-Cas systems, the length and sequence of the REC lobe varies among the 
different Cas9 orthologs. This explains the impossibility of Cas9 to function with 
tracrRNA:crRNA duplexes from divergent CRISPR-Cas systems (Fonfara et al., 2013).  
 
Biotechnological applications of Cas9 
The discovery that Cas9 can be guided to cleave any sequence that is next to the PAM 
(Jinek et al., 2012) quickly led to the development of genome-editing tools that are 
easily programmed to target virtually any gene of interest in almost any organism 
including human cells (Barrangou and Doudna, 2016; Jinek et al., 2012; Cong et al., 
2013; Doudna and Charpentier, 2014; Jinek et al., 2013; Makarova et al., 2011; Mali 
et al., 2013). Once Cas9 cleaves the desired sequence, the cell attempts to repair the 
DSB by non-homologous end-joining (NHEJ) or homology-directed repair (HDR). 
NHEJ is error-prone and may lead to gene knockout by introducing frameshift 
mutations. HDR uses a donor that bares homology to the break-flanking regions and, 
if provided exogenously, allows introducing a desired sequence in the target gene. 
The first modification to the natural system was fusing the tracrRNA:crRNA 
duplex to generate a single-guide (sg)RNA that can be transcribed as one molecule 
(Jinek et al., 2012). Then, inactivation of one or both nuclease domains allowed turning 
Cas9 into a nickase (n)Cas9 or a dead (d)Cas9, which is catalytically inactivated. 
nCas9 may be used to reduce the risk of cleaving undesired sequences (off-targets). 
By directing two nCas9 molecules to sequences that are in close proximity, a DSB is 
only generated when the two molecules cleave the desired sequence, reducing the 
risk of off-targets (Ran FA., et al 2013). 
 dCas9 can be used to repress transcription by targeting promoter regions. In 
addition, it can serve to guide effector proteins (such as transcriptional activators or 
methylases) to the region of interest by fusing them to dCas9 (Dominguez et al., 2016; 
Hilton et al., 2015; Kearns et al., 2015). The flexibility and programmability of this 
system means that new applications are constantly emerging.  
 
Non-canonical roles of the type II CRISPR-Cas systems 
Artificial modification of CRISPR components have generated systems with diverse 
functionalities, however some CRISPR-Cas systems have (naturally) evolved 
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functions beyond immunity (Louwen et al., 2014; Ratner et al., 2015; Westra et al., 
2014). Because type II systems are mostly found in pathogenic and commensal 
bacteria, (Chylinski et al., 2013; Fonfara et al., 2013; Sampson et al., 2013), the 
regulatory functions of these systems, and their role in virulence regulation have been 
studied. For example, cas9 deletion mutants in Streptococcus agalactiae, C. jejuni, N. 
meningitidis, and Francisella novicida are attenuated in virulence, attachment to or 
intracellular survival in host cells (Louwen et al., 2013; Ma et al., 2018; Sampson et al., 
2013). The type II-A S. agalactiae Cas9 (SagCas9) is involved in adherence to host 
cells and survival to phagocytosis by macrophages (Ma et al., 2018). Consequently, a 
strain deleted for cas9 is attenuated in virulence in murine and zebrafish infection 
models (Ma et al., 2018). Furthermore, SagCas9 was shown to repress the expression 
of the transcriptional regulator regR, which in turn inhibits the expression of the 
virulence factor hyaluronidase (Ma et al., 2018). SagCas9 was proposed to mediate 
degradation of regR mRNA due to partial complementarity with the CRISPR array (Ma 
et al., 2018). However, how SagCas9 promotes transcript degradation remains 
unknown. The type II-C Campylobacter jejuni Cas9 (CjCas9) is also involved in 
adhesion, invasion, translocation and cytotoxicity as observed by in vitro infection of 
cells (Louwen et al., 2013). Interestingly, a recent study has shown that CjCas9 can 
cleave RNAs that are complementary to the crRNA spacer in a tracrRNA-dependent 
manner (Dugar et al., 2018). RNA targeting by CjCas9 is PAM-independent and 
mediated by its HNH nuclease domain (Dugar et al., 2018). Although this raises the 
possibility that CjCas9 regulates gene expression by cleaving RNA, a direct link 
between RNA targeting and regulation of expression remains to be established. 
Similarly, Neisseria meningitidis Cas9 (NmeCas9), that is also type II-C, has been 
involved in virulence regulation (Sampson et al., 2013) and has a PAM-independent 
and RNA-mediated RNase activity in vitro (Rousseau et al., 2018) but the link between 
the RNase activity and gene regulation has not been established.  
A role in virulence has also been proposed for the CRISPR-Cas type II-B system 
in F. novicida. F. novicida is an intracellular pathogen used as a model to study the 
highly infectious and extremely virulent F. tularensis, which is the causative agent of 
tularemia and a potential bioweapon (Kingry and Petersen, 2014). Once F. novicida is 
phagocytized by the macrophages, it escapes the phagosome and replicates in the 
cytosol. At least two receptors can recognize intracellular F. novicida, the Toll-like 
receptor 2 (TLR2) and the AIM2/ASC inflammasome (Sampson et al., 2014).  
76 
Three CRISPR-Cas components have been shown to repress gene expression 
to facilitate virulence in F. novicida: Cas9, tracrRNA and the newly-described small-
CRISPR- associated scaRNA (Sampson et al., 2013). These elements are shown to 
regulate expression of the FTN_1103 gene, which codes for a bacterial lipoprotein 
(BLP) (Sampson et al., 2013). In the absence of any of these factors (but not other Cas 
proteins or the crRNA), expression of the FTN_1103 mRNA coding for a BLP is 
upregulated (Sampson et al., 2013). The increase in BLP synthesis was shown to 
disturb bacterial envelope integrity, which results in TLR2 and AIM2/ASC activation. 
This activation is likely a consequence of DNA escaping from the bacteria, which would 
activate both these receptors. As a result, BLP overproduction promotes inflammation 
and attenuates F. novicida virulence (Sampson et al., 2014). Interestingly, the double 
mutant lacking cas9 and FTN_1103 only partially restores virulence, suggesting there 
are additional factors that are regulated by Cas9 (Sampson et al., 2014). 
The mechanism by which expression of FTN_1103 is upregulated by Cas9 
remains unknown. Cas9, tracrRNA and scaRNA are part of the same mechanism as a 
triple deletion mutant shows the same effect as any of the single mutants (Sampson 
et al., 2013). scaRNA is encoded next to the CRISPR array in what appears to be a 
degenerated repeat. It is transcribed from a promoter in a former spacer and terminates 
within the next spacer, covering a complete degenerated repeat (Figure 11) (Chylinski 
et al., 2014). Furthermore, scaRNA is predicted to base-pair with tracrRNA, 
reminiscent of tracrRNA:crRNA base-pairing (Chylinski et al., 2014). These predictions 
are supported by point mutation analysis where substitutions in regions predicted to 
mediate the interaction have a similar effect than deleting any of the three components. 
In addition, repression of FTN_1103 was partially restored by compensatory 
substitutions that would regenerate the tracrRNA:scaRNA interaction (Sampson et al., 
2013). tracrRNA was also predicted to base-pair with the FTN_1103 mRNA in a region 
close to its RBS.  
Therefore, it was proposed that the tracrRNA:scaRNA duplex binds Cas9 and 
guides it to its target (FTN_1103 mRNA) promoting its degradation. However, the 
details of how Cas9 is guided and how the target is degraded or destabilized are 
unclear. In F. novicida Cas9 (FnoCas9), the HNH and RuvC-like domains, as well as 
the R-rich motif, are conserved. Substitutions in conserved amino acids of the nuclease 
domains (D11A and H969A for HNH and RuvC-like, respectively), which are essential 
for Cas9 activity in S. pyogenes (Jinek et al., 2012), do not affect FnoCas9-mediated 
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regulation of FTN_1103, indicating that the nuclease activity of Cas9 is not important 
for FTN_1103 regulation. However, the R59A substitution, located in the R-rich motif, 
shows the same effect than cas9 deletion. Furthermore, scaRNA, tracrRNA and the 
FTN_1103 mRNA were shown to co-immunoprecipitate with WT Cas9 but not with the 
R59A mutant, and FTN_1103 mRNA was shown to be less stable in the WT than in 
the Cas9 mutant (Sampson et al., 2013).  
The proposed model includes 3 steps: 1) tracrRNA:scaRNA:Cas9 complex 
formation, 2) targeting of FTN1103 mRNA by the complex through base-pair 
complementarity between tracrRNA and FTN1103 mRNA, 3) destabilization and 
degradation of the target mRNA by an unknown mechanism. 
 
Results 
The following work was done in collaboration with the group of David Weiss at Emory 
University in Atlanta, USA. The complete results are included in the manuscript entitled 
“Catalytically active Cas9 mediates transcriptional interference to facilitate bacterial 
virulence”, which at the moment of writing this thesis manuscript is under revision in 
the journal Molecular Cell. In this section, some additional results are described 
together with the summary of the main findings and conclusions. Please refer to the 
full manuscript currently in revision in Molecular Cell in the appendix section of this 
thesis manuscript for the figures and complete results.   
 
F. novicida (Fno)Cas9 binds and cleaves DNA specifically in vitro 
As mentioned above, tracrRNA, scaRNA and FnoCas9, negatively affect mRNA 
FTN_1103 expression by an unknown mechanism (Sampson et al., 2013). The aim of 
this study is to investigate the mechanism by which FnoCas9 regulates gene 
expression. With this in mind, we used purified FnoCas9 to analyze its biochemical 
properties in vitro. Though the functionality of FnoCas9 in immunity remains to be 
determined, its nuclease activity on the target DNA has previously been shown in vitro 
(Fonfara, I. et al. 2013). As a control to demonstrate that the purified FnoCas9 was 
catalytically active in our experimental conditions, we analyzed the binding and 
cleavage activities on a DNA fragment containing the target sequence. As expected, 
the Cas9:tracRNA:crRNA complex bound and cleaved a DNA target specifically, as 
shown by electrophoretic mobility shift assay (EMSA) and plasmid cleavage assay, 
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respectively (Figure 9. A-B). These results confirmed that our purified FnoCas9 was 
active in the tested conditions. 
 
 
Figure 9. FnoCas9 binds to and cleaves its 
target DNA. A) EMSA showing FnoCas9 
binding to a DNA fragment containing the target 
sequence in the presence of tracrRNA and a 
crRNA  B) Cleavage assay showing the specific 
DNA nuclease activity of FnoCas9. The 
supercoiled (sc) and linear (li) forms of the 
plasmid are indicated. The linear form is only 
observed in the presence of the 
tracrRNA:crRNA duplex and FnoCas9. The last 
lane contains no RNA duplex.  
 
FnoCas9 binds tracrRNA:crRNA and tracrRNA:scaRNA in vitro 
The fact that the FnoCas9 DNA nuclease activity is conserved suggests that the type 
II-B CRISPR-Cas system is also active in defense against DNA invasion, implying that 
FnoCas9 is able to bind both tracrRNA:crRNA and tracrRNA:scaRNA duplexes. In 
order to test this, we performed EMSA by incubating FnoCas9 with either 
tracrRNA:crRNA or tracrRNA:scaRNA preformed duplexes. As expected, Cas9 was 
able to bind both duplexes (manuscript Fig. S5), suggesting it might have dual function 
in defense and regulation.  
 
FnoCas9 specific binding to its potential RNA targets is not detected 
In order to investigate the mechanism by which FnoCas9 regulates FTN_1103, we 
evaluated its affinity to FTN_1103 mRNA by EMSA. To this end, we produced a 
fragment of the FTN_1103 transcript that contained the proposed interaction site with 
tracrRNA. However, while FnoCas9 binds to FTN_1103 in the absence of the duplex 
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RNA (Figure 10 A), the affinity did not increase upon addition of either tracrRNA, 
scaRNA or the performed duplex (Figure 10 B-D) suggesting that the binding to this 
RNA fragment is unspecific.  
To test the possibility that FnoCas9 binds in a different location of the transcript, 
we performed EMSA on the full-length FTN_1103 transcript, which includes FTN_1104 
(manuscript Figs. 1A and 1B). However, we failed to detect any specific binding of 
FnoCas9 to the mRNA (data not shown).  
RNAseq differential expression analysis comparing gene expression of the WT 
strain to deletion mutants of scaRNA, tracrRNA and Cas9 detected that FTN_1101 
was regulated in addition to the FTN_1103-FTN_1104 transcript (manuscript Figs. 1A 
and 1B). These results were also confirmed by Northern blot analyses (manuscript Fig. 
1C-E). However, FnoCas9 did not bind specifically to the FTN_1101 transcript either 
(data not shown). Together, these results suggested that FnoCas9-mediated gene 
regulation might require additional factors or different conditions.  
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Figure 10 FnoCas9 specific binding to its potential RNA targets is not detected. EMSA showing 
affinity of F. novicida Cas9 for isotopically labelled FTN_1103 mRNA by itself (A) or in the presence of 
scaRNA (B), tracrRNA (C) or scaRNA and tracrRNA (D). tracrRNA and scaRNA were used (Fig 1. B 
and C) in a concentration 1.5-fold higher than FTN_1103 mRNA. RNAs were incubated at 95 ℃ in 
Binding Buffer and let cool down slowly to room temperature. Then increasing concentrations of Cas9 
were added and the binding was analyzed by electrophoresis in polyacrylamide 6 % with 20 mM Tris-
acetate pH 8.5. 
 
FnoCas9 regulates its target genes via a conserved sequence in the 
5′ UTR that is complementary to scaRNA 
The absence of specific binding of FnoCas9 to its proposed target mRNAs in vitro led 
us to re-examine the regulating mechanism. In order to investigate the regions that are 
essential for gene regulation by FnoCas9, the 5′ UTR sequences of FTN_1101 and 
FTN_1104 were aligned. Interestingly, a region of 17 bp that was identical between the 
two sequences was identified (manuscript Fig. 2A). Furthermore, a reporter fusion was 
regulated by FnoCas9 when the 5′ UTR of any of the two genes was introduced 
downstream of the promoter, regardless of the promoter that was used (manuscript 
Fig. 2C-D).  
 In addition, 11 consecutive nt of scaRNA were predicted to base pair with the 
conserved sequences of FTN_1104 and FTN_1101 (manuscript Figs. 3A and B), 
suggesting that targeting might be mediated by scaRNA and not by tracrRNA. 
 
FnoCas9 interacts with the DNA of the regulated genes in a PAM-
dependent manner 
Further inspection of the adjacent sequences localized a putative PAM (TGG) 
sequence downstream of these regions (Figs. 3A and B). Moreover, substitutions that 
disrupted the putative PAM abrogated regulation of the reporter fusions by FnoCas9 
(manuscript Figs. 3C and 3D). Since the PAM is encoded in the non-target strand, 
these results indicated that FnoCas9 regulates its targets by binding to the DNA. 
Indeed, EMSA experiments showed that FnoCas9 interacted with a DNA target 
containing 11 bp of complementarity to scaRNA (manuscript Fig. 3E). Furthermore, 
this interaction was only observed in the presence of the PAM and the 
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tracrRNA:scaRNA duplex (manuscript Fig. 3E).  
 
The number of base pairs between scaRNA and the target DNA 
determines the level of transcriptional repression 
To evaluate the extent of scaRNA-DNA complementarity that FnoCas9 requires for 
gene regulation, we tested the expression of reporter fusions containing sequences 
with different numbers of base pairs to scaRNA (manuscript Fig. S3A). Higher 
complementarity of the target to scaRNA correlated with higher levels of repression of 
the reporter fusions (manuscript Fig 4A-F). In addition, the number of basepairs with 
scaRNA was also reflected in the affinity of FnoCas9 to the target DNA in vitro, the 
higher the complementarity the higher the affinity (manuscript Fig. 4A-F).  
scaRNA can mediate cleavage of complementary target DNA  
Interestingly, transformation efficiency of a plasmid containing 20 nt of 
complementarity to scaRNA was drastically reduced compared to plasmid with less 
complementarity, indicating that scaRNA can mimic crRNA function provided that there 
is enough complementarity with the target DNA (manuscript Fig. 4F).  
 
Transcription interference by FnoCas9 requires binding to a region 
in close proximity to the promoter 
Next, we investigated whether the distance of the target sequence to the promoter 
affected FnoCas9-mediated regulation. To this end, we tested the expression of 
reporter fusions with increasing distance to the promoter (manuscript Fig. 4H). While 
binding of FnoCas9 to the target was unaltered regardless of the distance to the 
promoter, repression was abrogated when the target sequence was placed 20 bp 
downstream of the transcription start site (manuscript Fig. 4H-K). This suggested that 
FnoCas9 binding was able to inhibit transcription initiation but not elongation.  
 
FnoCas9 forms two distinct complexes in the cell containing scaRNA 
or crRNA  
We hypothesized that two subpopulations of FnoCas9-complexes coexist in the cell, 
each containing one of the RNA duplexes. To test whether the levels of one of the 
duplexes influenced the abundance of the other, we performed Northern blot analyses 
in the WT and the deletion mutants for tracrRNA, scaRNA and crRNA and measured 
the abundance of the three ncRNAs. While the absence of scaRNA had no observable 
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effect on crRNA abundance, deleting crRNA caused a significant increase in scaRNA 
abundance (manuscript Fig. 5A-C). Furthermore, this increase in scaRNA abundance 
translated into a higher repression of the target genes (manuscript Fig. 5D-H). This 
indicated that FnoCas9 binding to scaRNA had a stabilizing effect. Moreover, these 
results suggest that crRNA and scaRNA seem to compete with crRNA for binding 
Cas9.  
 
Engineering scaRNA allows artificial regulation of desired genes 
Finally, to prove that this system can be used to repress other genes, we modified 
scaRNA to target the polymyxin resistance genes (FTN_0544 and FTN_0545) 
(manuscript Fig. 7A). As expected, targeting a region near the promoter of these genes 
resulted in a lower gene expression and a reduction in the resistance to this antibiotic 
(manuscript Fig. 7B-E). 
 
Discussion 
In this study, we showed that scaRNA guides FnoCas9 to bind downstream of the 
promoter of its target genes. Binding of FnoCas9 to the DNA interferes with 
transcription, repressing gene expression. Though FnoCas9 is able to cleave DNA, the 
limited complementarity of scaRNA with the DNA prevents digestion of the 
chromosome.  
Taken together, the results shown in this study suggest that FnoCas9 has a 
dual functionality. On the one hand, when bound to the tracrRNA:crRNA duplex, it 
maintains the classical immunity function. On the other, it has evolved the capability to 
regulate gene expression together with tracrRNA:scaRNA (Figure 11). 
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Figure 11 Scheme of the immunity and gene regulation mechanisms by the type II-B CRISPR-
Cas system of F. novicida. A) Representation of the CRISPR-Cas locus. Yellow and red arrows 
represent scaRNA and tracrRNA, respectively. Black squares and green diamonds indicate repeats 
and spacers, respectively. Putative degenerated repeats are shown as red squares, intercalated by 
spacers (white diamonds). Spacers that evolved to constitute scaRNA are shown in yellow. The 
confirmed and putative promoters of scaRNA are represented with solid or dotted bent arrows, 
respectively. The cas genes are indicated. B) Mechanisms of immunity and regulation. FnoCas9 
(blue) is guided by the crRNA:tracrRNA duplex to target and cleave DNA, constituting the immunity 
pathway (left). scaRNA:tracrRNA guides FnoCas9 to the regions adjacent to the promoters of the 
target genes, repressing transcription (right). Limited complementarity with scaRNA prevents 
cleavage. This figure is adapted and modified from (Chylinski et al., 2014). 
 
The mechanism discovered here, opens the possibility that regulatory functions 
of Cas9 are more widespread than previously thought. The fact that Cas9 is able to 
regulate gene expression while maintaining its role in immunity, means that evolution 
of this new functionality would not necessarily entail any evolutionary costs. It has been 
proposed that scaRNA evolved from degeneration the CRISPR array (Chylinski et al., 
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2014). A possible pathway for the evolution of this regulatory functionality might start 
with the acquisition of self-targeting spacers. Mutations in the spacers that prevent 
them from cleaving the DNA would allow the cell to survive. If the target region of this 
spacer is in close proximity to a promoter, it would repress the downstream gene. 
Evolution of an independent promoter driving transcription of this spacer would then 
allow regulation of the newly evolved function, independently of the expression of the 
immunity components. A bioinformatic search of partially self-targeting spacers with 
an independent promoter (and a terminator) should identify CRISPR-Cas systems with 
putative regulatory functions.  
In the case of F. novicida, repression of the BLPs is clearly advantageous, as it 
allows the cells to evade the immune system (Sampson et al., 2014). Yet, it is likely 
that under different conditions, BLP production is necessary. Future studies should 
investigate how the regulatory activity of FnoCas9 is regulated. It is likely that it is 
achieved by regulating scaRNA expression, since this would allow maintaining the 
immunity function of FnoCas9 unaltered.  
The newly discovered mechanism might also have implications regarding off 
target effects of Cas9. Traditionally, off-targets are defined as DSB in undesired 
locations. Our results show that limited complementarity between a guide RNA and the 
DNA is sufficient to repress transcription. Though the level of repression is likely to 
depend on the expression levels of Cas9 and the target DNA, this form of off-target 
effect might be significant in some conditions and should be considered.  
 
Materials and Methods 
For a detailed description of the experimental procedures, please refer to the 
manuscript in the appendix. In this section, only additional experiments (not shown in 
the manuscript) are described.  
 
 Table 6. List of primers used in the study. 
Code Sequence 5′-3′  F/Ra Usageb Reference 
Northern blot assays 
OLEC4268 CCAACAGCCTGCCTGCCACT R NB FTN_1101 This study 
OLEC4269 GTCTCCGTACTGTAACTTGC R NB FTN_RS05660 This study 
OLEC4274 ACCCAACTCACCATCGCCACA R NB FTN_1103 This study 
OLEC4276 TGGCAGCCAAAATGCGGTAG R NB FTN_1104 This study 
OLEC4323 ACCTACAGACCCTTTACGCC R NB 16S rRNA This study 
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OLEC2861 CTAACAGTAGTTTACCAAATAATTCAGCAACTGAAAC R 
NB crRNA This study 
OLEC2866 ATTACAGAGCATTAATTATTTGGTACATTTATAATTT R 
NB tracrRNA This study 
OLEC2864 AACACAAGTACATACCAAATAATCTAACAACTGAAAC R 
NB scRNA This study 
OLEC5225 ACCTACTTTCACCTGGGCAA R NB 5S rRNA This study 
RNA production 
OLEC4211 TAATACGACTCACTATA F IVT T7 promoter This study 
OLEC4407 
AAAAATAAGTAGGTCTAAAAGTGAATTTTCTAGC
TACTTTAAACTAACACAAGTACATACCAAATAAT
CTAACAACCTATAGTGAGTCGTATTA 
R IVT T7 scaRNA template 
with OLEC4211 This study 
OLEC3089 
GAAATTAATACGACTCACTATAGGATAACTCAAT
TTGTAAAAAAGTTTCAGTTGCTGAATTATTTGGT
AAAC 
F IVT T7 crRNA speM spacer (Fonfara et al., 2013) 
OLEC3090 
GTTTACCAAATAATTCAGCAACTGAAACTTTTTT
ACAAATTGAGTTATCCTATAGTGAGTCGTATTAA
TTTC 
R IVT T7 crRNA speM spacer (Fonfara et al., 2013) 
OLEC3102 GAAATTAATACGACTCACTATA GGGTACCAAATAATTAATGCTCTG F IVT T7-tracrRNA (processed) 
(Fonfara et 
al., 2013) 
OLEC3103 GTTATTCAGACGTGTCAAACAG R IVT T7-tracrRNA (Fonfara et al., 2013) 
OLEC4649 TAATACGACTCACTATAGGATCTAAAATTATAAATGTACCAAATAATTAATGC F 
IVT T7-tracrRNA 
(unprocessed)  This study 
OLEC4683 
AAAAATAAGTAGGTCTAAAAGTGAATTTTCTAGC
TACTTTAAACTAACACAAGTACATACCAAATAAT
CTAACAACTGAAACTTACAGCTAATCTTTTTCAT
TTGCTCCTATAGTGAGTCGTATTA 
R IVT T7-scaRNA (long) with OLEC4211  
DNA EMSAs 
OLEC9025 
TAAATACCAATTGACATATATAAATGATTCTGAT
ATAAATTAGATAAGGGAGGCCAACACTTGTCACT
ACTCTGACG 
F DNA EMSA  
0 bp complementarity)  This study 
OLEC9026 
CGTCAGAGTAGTGACAAGTGTTGGCCTCCCTTAT
CTAATTTATATCAGAATCATTTATATATGTCAAT
TGGTATTTA 
R DNA EMSA  
0 bp complementarity This study 
OLEC9027 
TAAATACCAATTGACATATATAAATGATTCTGAT
ATAAATTAGATAAGGGAGCTGTAATGGGGCCAAC
ACTTGTCACTACTCTGACG 
F DNA EMSA  
8 bp complementarity This study 
OLEC9028 
CGTCAGAGTAGTGACAAGTGTTGGCCCCATTACA
GCTCCCTTATCTAATTTATATCAGAATCATTTAT
ATATGTCAATTGGTATTTA 
R DNA EMSA 
8 bp complementarity This study 
OLEC9029 
TAAATACCAATTGACATATATAAATGATTCTGAT
ATAAATTAGATAAGGGATTAGCTGTAATGGGGCC
AACACTTGTCACTACTCTGACG 
F DNA EMSA  
11 bp complementarity This study 
OLEC9030 
CGTCAGAGTAGTGACAAGTGTTGGCCCCATTACA
GCTAATCCCTTATCTAATTTATATCAGAATCATT
TATATATGTCAATTGGTATTTA 
R DNA EMSA 
11 bp complementarity This study 
OLEC9031 
TAAATACCAATTGACATATATAAATGATTCTGAT
ATAAATTAGATAAGGGAAAGATTAGCTGTAATGG
GGCCAACACTTGTCACTACTCTGACG 
F DNA EMSA  
15 bp complementarity  This study 
OLEC9032 
CGTCAGAGTAGTGACAAGTGTTGGCCCCATTACA
GCTAATCTTTCCCTTATCTAATTTATATCAGAAT
CATTTATATATGTCAATTGGTATTTA 
R DNA EMSA 
15 bp complementarity This study 
OLEC9033 
TAAATACCAATTGACATATATAAATGATTCTGAT
ATAAATTAGATAAGGGATGAAAAAGATTAGCTGT
AATGGGGCCAACACTTGTCACTACTCTGACG 
F DNA EMSA  
20 bp complementarity   This study 
OLEC9034 
CGTCAGAGTAGTGACAAGTGTTGGCCCCATTACA
GCTAATCTTTTTCATCCCTTATCTAATTTATATC
AGAATCATTTATATATGTCAATTGGTATTTA 
R DNA EMSA 
20 bp complementarity This study 
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OLEC9035 
TAAATACCAATTGACATATATAAATGATTCTGAT
ATAAATTAGATAAGGGTTAGTATTAGCTGTAATG
GGGCCAACACTTGTCACTACTCTGACG 
F 
DNA EMSA  
11 bp complementarity  
5 bp from TSS 
This study 
OLEC9036 
CGTCAGAGTAGTGACAAGTGTTGGCCCCATTACA
GCTAATACTAACCCTTATCTAATTTATATCAGAA
TCATTTATATATGTCAATTGGTATTTA 
R 
DNA EMSA 
11 bp complementarity 
5 bp from TSS 
This study 
OLEC9037 
TAAATACCAATTGACATATATAAATGATTCTGAT
ATAAATTAGATAAGGGTTTACTTAGTATTAGCTG
TAATGGGGCCAACACTTGTCACTACTCTGACG 
F 
DNA EMSA  
11 bp complementarity 
10 bp from TSS 
This study 
OLEC9038 
CGTCAGAGTAGTGACAAGTGTTGGCCCCATTACA
GCTAATACTAAGTAAACCCTTATCTAATTTATAT
CAGAATCATTTATATATGTCAATTGGTATTTA 
R 
DNA EMSA  
11 bp complementarity 
10 bp from TSS 
This study 
OLEC9039 
TAAATACCAATTGACATATATAAATGATTCTGAT
ATAAATTAGATAAGGGAGAAATCCAATTTACTTA
GTATTAGCTGTAATGGGGCCAACACTTGTCACTA
CTCTGACG 
F 
DNA EMSA  
11 bp complementarity  
20 bp from TSS  
This study 
OLEC9040 
CGTCAGAGTAGTGACAAGTGTTGGCCCCATTACA
GCTAATACTAAGTAAATTGGATTTCTCCCTTATC
TAATTTATATCAGAATCATTTATATATGTCAATT
GGTATTTA 
R 
DNA EMSA  
11 bp complementarity 
20 bp from TSS 
This study 
 
 
Plasmid cleavage assay  
FnoCas9 was incubated with pEC691 (Fonfara et al., 2014) (containing the 
protospacrer and the PAM) for 1 h at 37 ℃ in the presence of the pre-formed 
tracrRNA:crRNA duplex. Reaction was done in KGB buffer (100 mM K-glutamate, 25 
mM Tris-acetate pH 7.5, 10 mM Mg-acetate, 10 ug/ml BSA, 0.5 mM ß-
Mercaptoethanol). After incubation, reaction was stopped by adding 3 µl stopping 
solution and samples were resolved by electrophoresis in a 0.8% agarose gel. 
 
DNA EMSA 
A tracrRNA:crRNA pre-formed duplex was incubated with FnoCas9 for 15 min at 37 ℃. 
Next, 1 nM target DNA was added (1:5 cold:hot) and incubated for 1 h at 37 ℃. 
Incubation was performed in Ca+2- containing binding buffer (20 mM tris-HCl pH 7.5, 
100 mM KCl, 5 mM CaCl+2, 5% Glycerol, 1 mM DTT). Samples were analyzed by 
PAGE in 6% PAA running buffer (0.5 x TBE 8pH, 5 mM CaCl+2). 
   
RNA EMSA 
FTN_1103 RNA transcript was produced by in vitro transcription using the 
AmpliScribe™ T7-Flash™ Transcription Kit (Epicentre) according to the 
manufacturer's instructions. The DNA template was produced by PCR using oligos 
(OLEC4405; TAATACGACTCACTATAGGATGCCCTGACTGCTCTCGTG and 
OLEC4406; CTTGCCACAACTGCCCAATATCAC).  1 nM of isotopically labelled 
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FTN_1103 RNA was incubated in 10 µl reactions with increasing concentrations of 
Cas9 either by itself or in the presence of scaRNA, tracrRNA, or tracrRNA:scaRNA  in 
concentration 1.5-fold higher than FTN_1103 mRNA. For pre-annealing, 
tracrRNA:scaRNA were incubated at 95 ℃ in RNA annealing buffer (1 M NaCl, 100 
mM HEPES, pH 7.5) and let cool down slowly to room temperature. Then increasing 
concentrations of Cas9 were added and the binding was analyzed by electrophoresis 
in polyacrylamide 6 % with 20 mM Tris-acetate pH 8.5. 
 
Contributions 
The work in this chapter was done in collaboration with the group of David Weiss at 
Emory University in Atlanta, USA. The experiments in F. novicida, including analysis 
of gene expression by qRT-PCR, were performed by the Weiss group. RNAseq 
analysis and the Northern Blot of the sRNAs were done by Anaïs Le Rhun in our 
laboratory. The study of Cas9 activity in vitro and the Northern Blot analysis to evaluate 
gene expression of Cas9 targets were done by myself. The experimental design and 
data analysis was performed jointly by the Weiss and the Charpentier groups (see also 
the “Authors contributions” section in the manuscript). 
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